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Abstract
The developing brain is especially vulnerable to the schizophrenia-inducing
effects of tetrahydrocannabinol (THC), the psychoactive chemical in cannabis. Although
the mechanisms underlying schizophrenia remains unclear, aberrant mesocorticolimbic
signaling and brain omega-3 deficiency may be involved. This study investigated chronic
prenatal THC’s effects on schizophrenia-associated behaviour as well as the neuronal
activity states and omega-3 levels in the mesocorticolimbic system. Behaviourally, THC
induced social memory impairments in male offspring whereas female exposure
increased anxiety and anhedonia. Electrophysiology revealed ventral tegmental area
dopamine hyperactivity and ventral hippocampus glutamate hyperactivity in male
offspring whereas female exposure induced glutamate hyperactivity in the prefrontal
cortex and ventral hippocampus. Lastly, matrix-assisted laser desorption/ionization
imaging mass spectrometry showed that THC induces omega-3 deficiency in the
prefrontal cortex, nucleus accumbens, and ventral hippocampus. These findings suggest
that prenatal THC may induce different schizophrenia-associated effects on male and female
offspring which calls for sex-specific treatments to counter THC’s effects.

Keywords: Cannabis, tetrahydrocannabinol, schizophrenia, locomotion, anxiety,
cognition, anhedonia, addiction, electrophysiology, ventral tegmental area, dopamine,
ventral hippocampus, prefrontal cortex, glutamate, MALDI, nucleus accumbens, omega3
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Summary for Lay Audience
Cannabis is commonly used by pregnant women for morning sickness relief.
Unfortunately, cannabis use during pregnancy may endanger their children’s brain
development. Cannabis contains a chemical called tetrahydrocannabinol that causes
adverse neurological effects. Evidence suggests that tetrahydrocannabinol exposure
during early stages of brain development such as adolescence induces symptoms
associated with schizophrenia, a disorder characterized by hallucinations, delusions,
emotional instability, and intellectual decline. However, the consequences of fetal
tetrahydrocannabinol are unclear; this is especially concerning since the concentration
of THC have dramatically increased over the last decade. Moreover, this lack of
knowledge may contribute to the widespread cannabis use by unknowing pregnant
women. Therefore, using pregnant rats, we examined the schizophrenia-associated
effects of maternal tetrahydrocannabinol exposure on the offspring and the
neurological changes associated with these behavioural abnormalities. Pregnant rats
received daily tetrahydrocannabinol injections (17 days) and their adult offspring
underwent behavioural tests that examined schizophrenia-associated symptoms such as
anxiety, locomotion, memory, sociability, depression-like behaviour, and propensity for
addiction. We found that tetrahydrocannabinol decreased memory in male offspring
only and induced anxiety and depression-like behaviour in only females. Next, we
examined tetrahydrocannabinol’s effects on schizophrenia-implicated brain regions
such as the ventral tegmental area, prefrontal cortex, and the ventral hippocampus. As
seen in schizophrenia patients, male offspring displayed increased ventral tegmental
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area activity as well as decreased ventral hippocampus activity that is characteristic of
the late stages of schizophrenia. In contrast, female offspring displayed increased
prefrontal cortex and ventral hippocampus activity which are typical of schizophrenia
patients. Finally, we measured brain levels of omega-3, a nutrient essential for proper
brain function, in schizophrenia-related brain regions since decreased brain omega-3 is
associated with schizophrenia. In males, tetrahydrocannabinol decreased omega-3
levels at 3-weeks and 6-months of age which suggests that tetrahydrocannabinol
induces persistent omega-3 deficits. In female offspring, only the 3-week old offspring
displayed omega-3 deficits which suggests that unlike males, females can recover from
these omega-3 deficits. Altogether, these findings suggest that fetal
tetrahydrocannabinol exposure leads to schizophrenia-associated effects. These findings
also raise the need for male and female-specific treatments to counter the
schizophrenia-inducing effects of tetrahydrocannabinol.
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1 Introduction

Cannabis (or marijuana), is cited to be the world’s most abused illicit substance.
The World Health Organization reports that the worldwide yearly prevalence rate of
cannabis use is almost 2.5% which equates to approximately 147 million people
(Bridgeman & Abazia, 2017). It is also believed that cannabis use has increased in recent
history (Degenhardt et al., 2018). Evidence suggests that there is growing public
acceptance for the consumption of recreational and medical cannabis in the United
States and Canada. For example, results from a Gallup poll in 2016 concluded that out of
the total surveyed American population, 60% are in favour of cannabis legalization.
Results from another poll by a 2016 Quinnipiac University in the United States reported
that 81% support medical cannabis legalization (Malloy, 2016). Furthermore, America
has seen an increase in the number states that legalized medical cannabis use (Bahji &
Stephenson, 2019). As of 2020, there are a total of 33 states that permit the
consumption of cannabis for medical purposes (Zarrabi et al., 2020). Recreational
cannabis has also been legalized in some states such as Colorado and California as well
as in countries such as Canada (Bahji & Stephenson, 2019). Therefore, it is not surprising
that compared to the rest of the world, America and Canada are thought to have a
particularly high prevalence of cannabis use disorders (Bahji & Stephenson, 2019). These
changing norms towards cannabis use may contribute to the development of a false
notion that cannabis is a safe and natural drug (Frau et al., 2019). However, recent
systematic reviews indicate that cannabis is indeed linked to deleterious psychiatric
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effects (Hindley et al., 2020; Marconi et al., 2016; Ortiz-Medina et al., 2018). One of the
primary phytochemicals found in cannabis is delta-9-tetrahydrocannabinol (THC), a
psychotropic compound, and both the potency and negative side effects of cannabis
have been attributed to its relative THC concentration (Lafaye et al., 2017). A substantial
number of clinical studies have reported that THC exposure is linked to psychotic and
psychiatric symptoms (Barkus et al., 2011; D’Souza et al., 2004; Morgan et al., 2018;
Morrison et al., 2009; Ranganathan et al., 2012). Emerging evidence from preclinical
studies also suggest that cannabis and THC exposure can induce schizophreniaassociated symptoms (Drazanova et al., 2019; Renard, Rosen, et al., 2017; Renard,
Szkudlarek, et al., 2017). Interestingly, however, studies show that cannabis exposure
during critical periods of neurodevelopment may pose greater risks for schizophrenia
than in adulthood. For example, Renard et al. (2017) demonstrated that adolescent THC
exposure induces neuropsychiatric behavioural symptoms such as anxiety, decreased
sociability, and memory impairments while THC treatment during adulthood results in
memory impairments only (Renard, Rosen, et al., 2017). A different study by Gleason et
al. reported that adolescent, but not adulthood exposure to WIN 55,212-2 (WIN), a
synthetic analog of THC (Hernández-Cervantes et al., 2019), induces schizophreniaassociated symptoms in mice (Gleason et al., 2012). Specifically, adolescent WIN
treatment lead to long-term deficits in learning and memory, as well as sensorimotor
gating (Gleason et al., 2012), the neurological process involved in the filtration of
sensory stimuli to inhibit subsequent motor responses (Ahmari et al., 2012; S. B. Powell
et al., 2012). Similarly, chronic WIN treatment during the pubertal period (PND 40 – 65),
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but not adulthood, has been shown to induce lasting impairments in sensorimotor
gating and recognition memory in rats (Schneider & Koch, 2003).
Emerging clinical data has also shown that fetal development may be a period at
which the developing brain is highly vulnerable to the psychotropic effects of cannabis.
Specifically, longitudinal studies have reported that potential neurological impairments
induced by prenatal THC exposure include psychosis (Fine et al., 2019), hyperactivity
(Day & Richardson, 1991; Fried, 1980), and increased vulnerability to addictive drugs (De
Genna et al., 2018). THC can be transferred through the placenta and accumulate in the
fetus (Gustafsson & Jacobsson, 2019). Moreover, given that both the placenta and fetal
brain express cannabinoid 1 receptors through which THC produces its effects, it is
plausible that prenatal cannabis exposure may have damaging effects on the developing
brain (Thompson et al., 2019). In addition to the clinical findings, recent preclinical data
indicates that prenatal THC exposure may increase the offspring’s sensitivity to the
psychoactive effects of acute THC administration. Specifically, Frau et al. (2019)
reported that while prenatal THC exposure alone did not induce sensorimotor gating
deficits, a subsequent THC challenge resulted in sensorimotor gating impairments in
prenatal THC-treated male offspring. Interestingly, these effects were not seen in the
female prenatal THC-treated offspring which suggests that prenatal THC may affect
neurodevelopment in male and female offspring differently (Frau et al., 2019). However,
the potential neurobiological mechanisms underlying such sex-dependent differences
have not been explained or investigated previously. In fact, current evidence regarding
the impact of cannabis on prenatal brain development is scarce (Frau et al., 2019). This
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is a major concern as cannabis is a treatment method that is commonly recommended
to help pregnant women cope with morning sickness (Dickson et al., 2018). Cannabis is
cited as the illicit drug that pregnant women use most often (Forray & Foster, 2015) and
there continues to be an uptrend (Alpár et al., 2016; Brown et al., 2017). The wide use of
cannabis among pregnant women may partially be attributed to the cannabis
legalizations and the perception that cannabis consumption is safe during pregnancy
(Thompson et al., 2019). It is plausible that this false perception stems from the lack of
studies that investigate the impacts of prenatal THC on the offspring. Therefore, the
present thesis will aim to elucidate the behavioural deficits induced by prenatal THC
exposure and the neurological changes that contribute to the onset of such behavioural
deficits. Furthermore, this thesis will investigate the pathological impact of prenatal THC
exposure in male and female offspring independently.

1.1 Introduction to Schizophrenia and Sex-Specific Differences

Schizophrenia is a deleterious neurological disorder and it is estimated that
approximately 1% of people will eventually develop schizophrenia in their lifetimes (Li et
al., 2016). Symptoms of schizophrenia can be divided into three main groups: 1.
Positive; 2. Negative; and 3. Cognitive (Stępnicki et al., 2018). The positive symptoms of
schizophrenia can be described as psychotic symptoms that healthy individuals do not
normally experience such as hallucinations, delusions, disordered thoughts, and
aberrant motor responses (Joseph et al., 2015; Patel et al., 2014). The negative
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symptoms of schizophrenia are symptoms that negatively affect one’s emotions and
behaviour which include lower expressivity of emotion, decreased frequency of goaloriented behaviour, and anhedonia (Patel et al., 2014). Finally, the cognitive
impairments seen in schizophrenia include deficits in communication skills, attention,
memory, and executive functioning (Mosiołek et al., 2016; Patel et al., 2014). In addition
to these three main groups of symptoms, however, schizophrenia is also known to be
linked to increased risk of anxiety (Temmingh & Stein, 2015) and substance abuse
(Winklbaur et al., 2006)
Evidence suggests that the prevalence of specific schizophrenia-related
symptoms, age of onset, and symptom severity is different between males and females
(Li et al., 2016) which suggests that there may be specific sex-dependent processes
implicated in the pathophysiology of schizophrenia. For example, female schizophrenia
patients have more affective symptoms that relates to emotion such as depression
(Cotton et al., 2009). Male patients on the other hand have a greater number of
negative symptoms and tend to develop schizophrenia earlier in their lifetimes (Segarra
et al., 2012). Furthermore, there is evidence that clinical symptoms such as memory
deficits and increased drug dependence may be more severe in male schizophrenia
patients compared to females (Cotton et al., 2009; Han et al., 2012) Altogether, this
suggests that female schizophrenia pathophysiology is different from that of males and
that females. However, the specific neurobiological mechanisms underlying the sexdependent differences in schizophrenia remains unclear (Li et al., 2016).
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1.2 Schizophrenia Pathophysiology

Schizophrenia has been studied for over a century but the exact physiological
processes that underlie schizophrenia pathophysiology are unknown (Patel et al., 2014).
This may be due to the fact that schizophrenia is a very heterogenous disorder with
several potential factors that may contribute to its onset (Wolfers et al., 2018). Genetics,
environmental factors, and the dysregulation of specific brain regions and neural
pathways may all contribute to the development of schizophrenia symptomology
(Wolfers et al., 2018). However, the majority of theories on schizophrenia
pathophysiology originate from the perturbations in neural signaling observed in the
disorder (Patel et al., 2014).
One of the main theories for the etiology of schizophrenia is the dopamine
hypothesis of schizophrenia (Howes et al., 2015) which suggests that schizophrenia
onset may be attributed to amplifications in dopamine signaling (Brisch et al., 2014). The
major study that lead to the proposition of the dopamine hypothesis found that the
augmentation of extracellular dopamine levels by amphetamine and other substances
are linked to schizophrenia-associated symptoms (Lieberman et al., 1987). These
findings were in line with earlier studies which showed that the reduction of dopamine
by specific drugs are associated with an attenuation of psychotic symptoms (Arnold &
Freeman, 1956; Carlsson et al., 1973; Wålinder et al., 1976). The dopamine hypothesis
of schizophrenia was further supported by subsequent evidence showing there is a
correlation between the efficacy of antipsychotic drugs and their level of affinity to
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dopamine receptors (Seeman & Lee, 1975). Currently, the mesolimbic hypothesis is one
of the main theories of schizophrenia pathophysiology and proposes that symptoms are
linked to dysregulation of dopamine signalling from the midbrain to structures in the
limbic system (McCutcheon et al., 2019).
The dopamine neurons of the mesolimbic dopamine pathway originate from the
ventral tegmental area (VTA) (Arias-Carrián et al., 2010), one of the main dopaminergic
regions located in the midbrain (Juárez Olguín et al., 2016). The mesolimbic dopamine
system primarily consists of dopamine projections from the VTA to the NAc (AriasCarrián et al., 2010). However, the system also includes dopamine projections to other
regions such as the hippocampus (Arias-Carrián et al., 2010). Outside of the mesolimbic
dopamine system, the VTA also has dopamine projections to cortical brain regions such
as the prefrontal cortex (PFC) (Arias-Carrián et al., 2010; Gorelova et al., 2012). The NAc,
hippocampus, and PFC are all implicated in the modulation of VTA dopamine release.
For example, the NAc regulates VTA dopamine release through two different pathways.
First, the NAc directly projects inhibitory GABA neurons to the VTA GABAergic
interneurons, and to a lesser extent, the VTA dopaminergic neurons (Russo & Nestler,
2013). In the second pathway, the NAc indirectly regulates VTA dopamine signaling
through GABAergic projections to the ventral pallidum which primarily innervates the
VTA dopamine neurons through GABAergic projections to the VTA (Loureiro et al., 2015;
Russo & Nestler, 2013). Thus, greater glutamatergic stimulation of the NAc inhibits the
ventral pallidum’s inhibitory input on the VTA and ultimately enhances VTA dopamine
release (Lodge & Grace, 2011). The ventral hippocampus (vHipp) is one such structure
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that exerts excitatory stimulation onto the NAc through glutamatergic projections
(Lodge & Grace, 2011). Lastly, the PFC provides an excitatory tone onto the VTA through
glutamatergic projections (Almodóvar-FÁBREGAS et al., 2002)
Fig. 1

Figure 1: The VTA releases dopamine into the PFC and NAc. The PFC sends excitatory glutamatergic
projections to the VTA. The NAc regulates VTA dopamine activity mainly through the GABA projections
from the NAc to the ventral pallidum (VP). This inhibits the VP’s inhibitory influence on VTA dopamine
neurons. The vHipp regulates VTA dopamine activity through its glutamatergic projections to the NAc.

Given their important roles in the modulation of the mesocorticolimbic
dopamine system signaling, it is not surprising that abnormalities of the NAc (McCollum
et al., 2015; McCollum & Roberts, 2015), anterior hippocampus (Medoff et al., 2001;
Suddath et al., 1990) (the human analog of the rodent vHipp) (Grace, 2012), and PFC
(Buchanan et al., 1998; Gur et al., 2000) have been found in schizophrenia patients. For
example, there is clinical evidence that the NAc of schizophrenia patients may have
specific alterations that lead to greater reception of glutamatergic excitatory inputs
(McCollum et al., 2015; McCollum & Roberts, 2015) which would inhibit ventral pallidum
GABAergic outputs and ultimately enhance VTA dopamine release (Lodge & Grace,
8

2011). Specifically, McCollum et al. found that in schizophrenia patients, the core region
of the NAc (NAcc) contains more excitatory synapses compared to controls (McCollum
et al., 2015). In a subsequent study, McCollum et al. also found an increase in the
concentration of vesicular glutamate transporter 2, a protein implicated in glutamate
uptake and storage, in the NAc of schizophrenia patients (McCollum & Roberts, 2015).
These transporters are known to be essential for glutamatergic synapses to function
adequately (Herman et al., 2014). In schizophrenia patients, there is also evidence that
the anterior hippocampus is reduced in size (Suddath et al., 1990) and that there is
hyperactivity within this region (Medoff et al., 2001). Moreover, studies show that
schizophrenia is associated with smaller white and grey matter volumes in the PFC
(Buchanan et al., 1998; Gur et al., 2000). As for whether PFC hyperactivity or
hypoactivity is implicated in schizophrenia, there appears to be mixed results (Paz et al.,
2008). More recent evidence, however, suggests that instead of hypoactive glutamate
signaling, amplified glutamate may underlie schizophrenia (Moghaddam & Javitt, 2012).
The newly modified glutamate hypothesis makes the proposition that schizophrenia
symptoms stem from pathologically amplified glutamate activity in the PFC among other
regions (Krystal et al., 2003; Moghaddam, 2003). This new glutamate hypothesis better
fits the mesolimbic dopamine hypothesis because the PFC stimulates the VTA through
its glutamatergic projections (Almodóvar-FÁBREGAS et al., 2002). This dysregulation of
glutamatergic neurons may be attributed to decreased GABAergic signaling in
schizophrenia (Egerton et al., 2017). Studies have consistently linked schizophrenia with
GABAergic dysfunction in the hippocampus and PFC. For example, multiple studies
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suggest that schizophrenia is associated with a decrease in glutamic acid decarboxylase
67 (GAD67), the primary enzyme responsible for GABA synthesis (de Jonge et al., 2017),
in the hippocampus (Benes et al., 2007; Knable et al., 2004) and in the PFC (Akbarian et
al., 1995; Guidotti et al., 2000; Mirnics et al., 2000; Volk et al., 2000). All GABAergic cells
in the PFC and hippocampus are interneurons that regulate the glutamatergic signaling
output from these regions (Coyle, 2004). Therefore, it is possible that the decrease in
GABA interneuron signaling leads to the augmented PFC and hippocampus
glutamatergic output associated with schizophrenia.

1.3 Schizophrenia and the Endocannabinoid System

The endocannabinoid system is the biological signaling system involved in the
regulation of various physiological processes that include development (Lu & MacKie,
2016), cardiovascular function, metabolism, immune responses, and gastrointestinal
function (Mouslech & Valla, 2009), as well as neural functions such as motivation,
emotion and cognition (Campolongo & Trezza, 2012). The main endogenous agonists of
the endocannabinoid system include 2-arachidonoyl glycerol (2-AG) and anandamide
(AEA) (Mouslech & Valla, 2009). Both of these endocannabinoids produce their effects
through the activation of the two G-protein-coupled-receptors cannabinoid receptor 1
(CB1) and the cannabinoid receptor 2 (CB2) (Mouslech & Valla, 2009). The primary role
of CB2 is to regulate immune functions and are therefore found in the immune system
(Mouslech & Valla, 2009). In the central nervous system, the main cannabinoid receptor
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is CB1 and are expressed at the pre-synapse (Lu & MacKie, 2016) of both the
glutamatergic and GABAergic synapses (Mouslech & Valla, 2009). In response to
postsynaptic activation, endocannabinoids are synthesized (Zou & Kumar, 2018) and
released from the post-synapse to activate CB1 on the pre-synapse (Kano, 2014).
Through this process called retrograde signaling (Kano, 2014), endocannabinoids
regulate inhibitory GABA and the excitatory glutamate neurotransmission (Mouslech &
Valla, 2009).
CB1 is found in key brain regions such as the PFC and vHipp and evidence
suggests that endocannabinoid system signaling in these regions is responsible for the
regulation of mesolimbic dopamine system signaling (Silveira et al., 2017). These
findings raise the possibility that abnormalities within the endocannabinoid system
underlie schizophrenia pathophysiology. Although more studies are necessary to gain a
comprehensive understanding of the endocannabinoid system’s role in this disorder,
there is evidence of increased CB1 signaling in schizophrenia. Specifically, CB1 appears
to be expressed at higher concentrations in certain brain regions that regulate
mesolimbic dopamine activity such as the PFC (Dalton et al., 2011; Dean et al., 2001)
and hippocampus (Desfossés et al., 2010) of schizophrenia patients. Moreover,
treatment with CB1 agonists such as THC has been shown to amplify mesolimbic
dopamine system signaling (Jianping et al., 1990; Pistis et al., 2001). It is believed that
CB1 activation is responsible for the psychoactive properties of THC (Mackie, 2006) and
evidence suggests that chronic THC exposure during critical neurodevelopmental
periods induces persistent VTA dopamine hyperactivity (Frau et al., 2019; Renard,
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Szkudlarek, et al., 2017). Specifically, chronic THC exposure during adolescence
augments baseline VTA dopamine neuronal activity at adulthood while chronic THC
exposure during adulthood has no effect (Renard, Szkudlarek, et al., 2017). Prenatal THC
exposure has been shown to induce a similar effect where male offspring demonstrate a
significantly higher baseline firing frequency of VTA dopamine neurons (Frau et al.,
2019). Altogether, these findings point to the possibility that amplified CB1 activation
may underlie mesolimbic dopamine hyperactivity in schizophrenia and that this is the
process through which chronic THC may lead to the onset of schizophrenia
symptomology.

1.4 Omega-3 Polyunsaturated Fatty Acids and its Link to Schizophrenia

Polyunsaturated fatty acids (PUFA) are a group of lipids that include the essential
human nutrients, omega-3 and omega-6 fatty acids (Kitajka et al., 2004). These fatty
acids are incorporated into the phospholipid membranes (Ander et al., 2003) of every
cell where they regulate membrane fluidity (Yu et al., 2015) which is necessary for
proper signaling within and across the cell membrane (G. Schmitz & Ecker, 2008). For
example, high omega-3 levels in the neuronal cell membranes induces the synthesis of a
phospholipid called phosphatidylserine which upregulates the PI3K/Akt pathway
involved in neuronal survival (Akbar et al., 2005). The brain is the tissue that has the
highest concentration of PUFA (Moore, 2001) and omega-3 is required for several
neuronal processes such as signal transmission, transcription, and ion channel
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functioning (Young & Conquer, 2005). Interestingly, both clinical and preclinical studies
show that omega-3 deficiency is linked to symptoms of anxiety and depression (Carrié et
al., 2000; DeMar et al., 2006; Harauma & Moriguchi, 2011; Larrieu & Layé, 2018;
McNamara, Hahn, et al., 2007). Moreover, omega-3 deficiency has been shown to
induce mesolimbic dopamine system hyperactivity (Zimmer et al., 2002). Together,
these findings suggest that insufficient omega-3 may be implicated in schizophrenia
etiology. Indeed, two meta-analyses have shown that schizophrenia patients have lower
blood concentrations of omega-3 (Hoen et al., 2013; van der Kemp et al., 2012) and this
may translate to reduced brain omega-3 levels given that the blood is involved in
omega-3 delivery to the brain (Weiser et al., 2016). Another post-mortem study
reported that the orbitofrontal cortex of male schizophrenia patients have a 20%
reduction in docsahexaenoic acid (DHA) (McNamara, Jandacek, et al., 2007), the most
prominent omega-3 in the brain (Dyall, 2015)
The specific mechanisms underlying the involvement of omega-3 in
schizophrenia pathophysiology remains unknown (Qiao et al., 2020). However, brain
omega-3 is involved in endocannabinoid signaling (Dyall, 2017) which raises the
possibility that this is a mechanism through which omega-3 influences mesolimbic
dopamine signaling (Zimmer et al., 2002) and the resultant schizophrenia symptomology
(McCutcheon et al., 2019). One of the possible ways that omega-3 regulates mesolimbic
dopamine signaling is through the modulation of endocannabinoid levels. DHA is
metabolized into the endocannabinoids 2-docosahexaenoylglycerol and Ndocosahexaenoylethanolamine (DHEA) (Dyall, 2017). Eicosapentaenoic acid (EPA), a less
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prominent omega-3 in the brain (Healy-Stoffel & Levant, 2018), is metabolized into the
endocannabinoids 2-eicosapentaenoylglycerol and 2-eicosapentaenoylethanolamine
(EPEA) (Dyall, 2017). The endocannabinoids 2-AG and AEA are produced within the
membrane from ARA, an omega-6 fatty acid (Dyall, 2017). Among the
endocannabinoids, 2-AG and AEA demonstrate the strongest affinity to CB1 (BoschBouju & Layé, 2016). It is possible that enhanced omega-3 concentrations may reduce 2AG and AEA levels due to competition between omega-3 and ARA for endocannabinoid
synthesis pathways. Specifically, DHEA and EPEA are produced via the same pathways as
AEA. Furthermore, ARA within the membrane are replaced by DHA and EPA (Dyall,
2017). These pieces of evidence are consistent with findings that greater omega-3
consumption reduces the abundance of 2-AG and AEA in the brain but increases omega3-based endocannabinoids (Artmann et al., 2008; Batetta et al., 2009; Matias et al.,
2008; Watanabe et al., 2003; Wood et al., 2010). Given that the omega-3-based
endocannabinoids have a lower affinity for CB1 than AEA and 2-AG (Bosch-Bouju & Layé,
2016), the above findings suggest that lower omega-3 levels in the brain may enhance
CB1 signaling. As mentioned previously, chronic CB1 activation by THC (Mackie, 2006)
may be the mechanism through which long-term THC exposure during
neurodevelopment induces schizophrenia symptomology (Renard, Szkudlarek, et al.,
2017). Thus, it is plausible that omega-3 deficiency in the brain may be implicated in the
schizophrenia-related symptoms linked to THC.
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1.5 Research Aims and Hypothesis

The present thesis project is based on previous findings from our laboratory that
chronic THC exposure during adolescent neurodevelopment induces schizophreniarelated symptomology (Renard, Szkudlarek, et al., 2017). This project also builds on a
similar study that prenatal THC exposure enhances baseline VTA dopamine activity in
male offspring but does not impair their behaviour unless given subsequent THC
injections (Frau et al., 2019). In that study, however, a considerably lower dose of THC
was used compared to our adolescent THC protocol (2mg/kg vs 3mg/kg) and ran limited
behavioural assays (Frau et al., 2019). Furthermore, the mechanisms underlying THC’s
effects on dopamine system regulation has not been fully elucidated (Frau et al., 2019).
Therefore, this thesis project will investigate the following three aims:
1. To investigate in male and female offspring the effects of a higher dose of
chronic prenatal THC on a wider range of behavioural measures associated with
schizophrenia which consists of: locomotion (Van Den Buuse, 2010); anxiety
(Dernovšek & Šprah, 2009; Grillo, 2018; C. M. Powell & Miyakawa, 2006);
sociability (Dodell-Feder et al., 2015; C. M. Powell & Miyakawa, 2006); memory
(Aleman et al., 1999); anhedonia (Horan et al., 2006); and drug-dependence
(Khokhar et al., 2018).
2. To study in male and female offspring the effects of chronic prenatal THC on the
baseline activity of the VTA, PFC, and vHipp neurons and determine how they
relate to the dopamine hypothesis of schizophrenia.
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3. To explore the levels of DHA in the PFC, NAc, and vHipp as a potential
mechanism involved in the regulation of VTA dopamine regulation.

General Hypothesis: Chronic prenatal THC exposure will induce schizophreniaassociated behavioural deficits as well as perturbations in VTA dopamine system
regulation and DHA concentrations.

Specific Predictions:
1. Chronic prenatal THC exposure will induce deficits in emotion, cognition,
sociability, and drug sensitivity in male and female offspring.
2. Both female and male offspring exposed to THC will exhibit hyperactivity in the
VTA, PFC, and vHipp which are neurological activity states linked to increased
VTA dopamine activity.
3. Prenatal THC will reduce DHA levels in the PFC, NAc, and vHipp of male and
female offspring which may contribute to schizophrenia-associated behavioural
and neuronal activity states.
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2 Methods

2.1 Drug Preparation

THC dissolved in ethanol was mixed with cremophor and saline at a 1:1:18 ratio.
Nitrogen gas was then blown on the solution to fully evaporate the ethanol. To make
the vehicle solution, cremophor and saline was mixed at a 1:18 ratio.

2.2 Subjects

The procedures in the current thesis project commenced after approval. All
procedures were approved by Western University’s Animal Care Committee in
accordance with regulations set by the Canadian Council on Animal Care. A total of n=15
Pregnant female Wistar rats (250g) were obtained from Charles River located in Quebec,
Canada at gestational day 3. All pregnant dams were undisturbed for three days to
acclimatize to the animal care facility holding room at Western University. The dams
were single-housed and maintained in holding rooms with 12-hour light/dark cycles
(lights on starting at 07:00 and off at 19:00) and constant temperature (22oC). Food and
water were provided ad libitum.
At gestational day 6, dams were randomly assigned to the vehicle group (n=8) or
THC treatment group (3mg/kg; n=7) and drugs were administered once daily from
gestational day 6 to 22 intraperitoneally (i.p.). This dose was selected as it leads to THC
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levels in the serum found in cannabis users (Falcon et al., 2012; Klein et al., 2011; Natale
et al., 2020; Schwope et al., 2011) and drug administrations began at gestational day 6
because THC exposure before this timepoint increases the risk of spontaneous abortions
(Dinieri & Hurd, 2012). Previous studies have successfully utilized this dose and method
of delivery (Chang et al., 2017; Holloway et al., 2014; Natale et al., 2020; Tortoriello et
al., 2014) and reported no significant effects on maternal weight, maternal food intake,
length of gestation, male to female ratio of the litter, and the litter size (Natale et al.,
2020; Tortoriello et al., 2014). When pups were delivered, litter sizes were culled to 8
and their mothers were left to care for their offspring. After weaning, male and female
offspring were housed separately in groups. The male holding rooms only contained
male offspring whereas female holding rooms only contained female offspring. At 9weeks of age, the offspring were single-housed. Behavioural and electrophysiology
experiments began when offspring were 10-weeks of age. Behavioural experiments and
electrophysiology experiments ended when offspring were 17-weeks and 23-weeks of
age respectively. MALDI experiments were conducted at 3-weeks and 6-months of age.
A few offspring from an additional 16 dams (VEH; n=7 and THC; n=9) from a separate
cohort were used to increase the n-size for MALDI experiments. These dams underwent
the same protocol as described above and only the vehicle and THC offspring from the
same cohort were compared. The experiment used a between-subjects design meaning
that all offspring were selected for either behavioural, electrophysiology, or MALDI
experiments. No offspring underwent more than one type of experiment.
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An issue concerning the use of offspring from multiparous species is that having
similar genes and living environments could induce similar experimental outcomes in
littermates (Zorrilla, 1997). To minimize these effects, care was taken to evenly
distribute the dams’ offspring among the behavioural, electrophysiology, and MALDI
IMS experiments. Specifically, 1-3 offspring were randomly selected from litters for the
experiments.

2.3 Behavioural Experiments

2.3.1 Open Field Test
The avoidance of an open, unprotected region such as the center of an open
field is a reflection of anxiety (Ohl, 2003) and the measurement of ambulatory distance
can be used to measure locomotion and confirm whether any effects observed in other
behavioural procedures may be due to changes in locomotor activity. To measure
anxiety and locomotion, rats were put into an automated open-field activity chamber
(Med Associates) to measure the time spent in the center, number of entries into the
center, and total distance travelled for 10 minutes.
The open field test was used because in addition to being able to measure
differences in locomotion, it can also compare anxiety levels. With both results, effects
on locomotion and anxiety may be better interpreted. For example, a seemingly
anxiolytic effect indicated by less time spent in the center zone could be due to
decreased locomotion instead. If there were no differences in locomotion, however, this
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would increase our confidence that the decreased time spent in the center reflects
increased anxiety.

2.3.2 Light Dark Box Test

The light dark box test is another anxiety test and is based on rodents’ natural
inclination toward dark/closed areas to avoid predators (Lezak et al., 2017). This light
dark box apparatus was made up of two compartments with the dimensions 50 x 25 x
37cm. Between the 2 compartments was a 10 x 10cm opening that allow rats to freely
enter both compartments. The “light” compartment was the white compartment with
an open roof. This “light” compartment was illuminated by a lamp (1500 lux). The “dark”
compartment was the black compartment that is closed by a lid. Rats were put into the
light compartment facing the wall opposite from the opening and recorded four
different measurements for 10 minutes: 1. Latency to make the first transition into the
dark compartment; 2. Latency to make the second transition into the light
compartment; 3. The number of transitions between the light and dark compartments;
and 4. The total time spent in the light compartment. An anxiogenic effect can be
inferred by decreased time spent in the light compartment and increased latencies to
enter light compartment (Lezak et al., 2017). An entry into the light or dark
compartment was an event when all 4 paws of the rat entered the compartment.
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2.3.3 Novel Object Recognition Test

The novel object recognition test is a procedure used to measure memory
(Antunes & Biala, 2012). The procedure is based on animals’ innate tendency to prefer
novelty over familiarity (Antunes & Biala, 2012). The novel object recognition test
apparatus was an open arena (80 x 80cm) without a roof covering the arena. One day
prior to the testing day, rats were habituated to the arena for 20 minutes. On the testing
day, there were 2 trials for each rat. In the first trial (acquisition trial), 2 identical objects
were placed on the corners of one side of the arena 15cm away from the walls. The rat
was placed on the side of the arena opposite of the objects. The rats were left alone to
explore the objects and returned to their cages after 3 minutes. After a 1-hour period,
the rats were returned to the same arena with one of the familiar objects replaced with
a novel object. The time spent exploring the novel and familiar objects were recorded.
Exploration activity was considered to be events when the rats’ noses were pointing at
the objects and/or the rats were sniffing the objects. The object recognition index was
calculated using the formula: ((novel object exploration time/total exploration time of
both objects) *100). Because animals will naturally prefer the novel object (Antunes &
Biala, 2012), a lower object recognition index may indicate decreased short term
memory.
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2.3.4 Spontaneous Alternation Y-Maze Test

The spontaneous alternation Y-maze test measures working memory (Kraeuter
et al., 2019). This procedure is based on the rodents’ natural tendency to investigate
spaces that they did not explore previously (Kraeuter et al., 2019). The Y-maze
apparatus consisted of 3 non-elevated arms 50cm long and 120o apart from each other.
The arms were covered by a 40cm high wall. Rats were placed into one end of the arm
facing the center and left to explore the maze. For 10 minutes, the sequence of entries
into the arms was recorded. The alternation score was calculated using the formula:
(number of unique triplets/(total arm entries-2)) where a unique triplet was an event
when a sequence of 3 entries included 1 of each arm. Because animals will naturally
investigate arms that they did not explore previously (Kraeuter et al., 2019) a lower
alternation score may indicate decreased working memory.

2.3.5 Social Interaction Test

The social motivation and the social memory phases of the social interaction test
was used to measure the motivation for social behaviour and social recognition memory
respectively. The social interaction test apparatus was made up of 3 compartments
separated by guillotine doors that could slide out to create an opening to all 3
compartments. On the day before testing day, rats were habituated to the center
compartment for 5 minutes with the guillotine doors closed followed by another 8-
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minute habituation period with the guillotine doors open. On testing day, rats were first
placed in the center compartment for 5 minutes with the guillotine doors closed. After
this period was the social motivation phase where one empty wired enclosure cage was
placed on one of the side compartments while a wired enclosure with an unfamiliar rat
was placed on the other compartment. The guillotine doors were removed, and the test
subjects were left to explore the apparatus for 8 minutes. During this time, the
exploration times of the empty wired enclosure and stranger rat were recorded. The
sociability score was calculated using the formula: ((exploration of stranger rat/total
exploration time of empty enclosure and stranger rat)*100). A lower sociability score
would indicate decreased sociability. After phase 1 was the social memory phase where
the empty wired enclosure was removed and stuffed with a novel rat. This enclosure
was placed back into the compartment and the subjects’ exploration of the novel and
familiar rats were recorded for 8 minutes. The social recognition score was determined
with the formula: ((exploration of novel rat/total exploration time of novel and familiar
rat)*100). Because rats prefer novelty over familiarity (Antunes & Biala, 2012), the rats
should spend more time exploring the novel rat vs the familiar rat. Therefore, lower
social recognition score may indicate decreased social recognition memory. Exploration
activity was an event when the rats’ nose was pointing at the enclosure and/or when
the rat was sniffing at the enclosure.
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2.3.6 Sucrose Preference Test

The sucrose preference test is a procedure used to measure anhedonia (DerAvakian & Markou, 2012) and is based on the fact that rats, like humans, find foods such
as sucrose pleasurable (Scheggi et al., 2018). Rats were provided 2% sucrose solution ad
libitum from a bottle in their home cages for 48 hours but were deprived of water. After
this period, the sucrose solution was removed, and the rats were not given access to the
sucrose solution or water for 12 hours. Then for 1 hour, rats were given access to a
bottle filled with water and a bottle filled with the sucrose solution. The volume of
water and sucrose solution consumed was recorded after the testing phase. The sucrose
preference score was calculated using the formula: ((volume of sucrose solution
consumed/total volume of sucrose and water consumed)*100). Thus, a lower sucrose
preference score would be indicative of anhedonia (Der-Avakian & Markou, 2012).

2.3.7 Sub-Threshold Morphine Conditioned Place Preference Test

The sub-threshold morphine conditioned place preference test is used to
measure drugs’ motivational effects (Tzschentke, 2007). In this procedure, subjects
develop a preference for a specific environment by pairing the environment with a
rewarding stimulus (Huston et al., 2013). Two different conditioning environments were
used. One of the environments was white with a wire mesh floor covered with wood
chips. The other environment was black with a smooth plexiglass floor with 1ml of acetic
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acid (2%) spread on the floor. Previous experimentation has shown that rats do not
demonstrate a significant baseline preference for either of these environments
(Laviolette & Van Der Kooy, 2003). One day before the start of the conditioning phase,
rats were placed in a neutral grey environment for 20 minutes. Then the conditioning
phase lasted for 8 straight days. Once per day, rats received intraperitoneal injections of
either vehicle (saline) or subthreshold morphine (0.05mg/kg) in alternation.
Immediately after the injection, rats were placed in the environment previously
assigned to the vehicle and subthreshold morphine for 30 minutes. For example, in half
of the rats, the saline was assigned to the white context while morphine was assigned to
the black context. In the other half, saline was assigned to the black context while
morphine was assigned to the white context. The assignment of the environments and
the order of injections were fully counterbalanced. One week after the conditioning
phase, the rats were tested in a drug-free state. The conditioned place preference
testing apparatus was composed of one of each environment on either side separated
by a grey neutral zone. Rats were placed on the neutral zone and the time spent in each
of the environments were recorded for 10 minutes. Rats were considered to be inside
an environment when all 4 paws were within the environment. The preference for the
morphine-paired environment was determined using the formula: ((time in morphinepaired environment/total time spent in both morphine- and vehicle-paired
environments)*100). Previous experimentation has shown that the 0.05mg/kg
morphine dose does not induce significant preference effects (Ahmad et al., 2013).
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Thus, a result that suggests a significant preference for the subthreshold morphine
environment would indicate an increased sensitivity to morphine.

Assay
Open field

Sex Group
M
F

Light-dark
box

M
F

Novel object
recognition

M
F

Social
interaction

M
F

Spontaneous M
alternation
Y-maze
F
Sucrose
preference

M
F

Conditioned
place
preference

M
F

VEH
THC
VEH
THC
VEH
THC
VEH
THC
VEH
THC
VEH
THC
VEH
THC
VEH
THC
VEH
THC
VEH
THC
VEH
THC
VEH
THC
VEH
THC
VEH
THC

nsize
10
10
12
12
10
8
11
12
10
10
12
12
9
10
12
12
10
10
11
12
10
9
12
10
10
9
12
12

Dam ID that provided offspring and
(# of offspring)
17(2); 18(1); 19(1); 20(1); 22(2); 23(2); 24(1)
58(1); 59(2); 60(1); 61(1); 62(2); 63(2); 64(1)
17(2); 22(3); 23(2); 24(2); 25(3)
58(2); 60(1); 61(2); 62(2); 63(2); 64(3)
17(2); 18(1); 19(1); 20(1); 22(2); 23(2); 24(1)
59(2); 60(1); 61(1); 62(2); 63(1); 64(1)
17(1); 22(3); 23(2); 24(2); 25(3)
58(2); 60(1); 61(2); 62(2); 63(2); 64(3)
17(2); 18(1); 19(1); 20(1); 22(2); 23(2); 24(1)
58(1); 59(2); 60(1); 61(1); 62(2); 63(2); 64(1)
17(2); 22(3); 23(2); 24(2); 25(3)
58(2); 60(1); 61(2); 62(2); 63(2); 64(3)
17(2); 18(1); 19(1); 20(1); 22(2); 23(1); 24(1)
58(1); 59(2); 60(1); 61(1); 62(2); 63(2); 64(1)
17(2); 22(3); 23(2); 24(2); 25(3)
58(2); 60(1); 61(2); 62(2); 63(2); 64(3)
17(2); 18(1); 19(1); 20(1); 22(2); 23(2); 24(1)
58(1); 59(2); 60(1); 61(1); 62(2); 63(2); 64(1)
17(2); 22(3); 23(1); 24(2); 25(3)
58(2); 60(1); 61(2); 62(2); 63(2); 64(3)
17(2); 18(1); 19(1); 20(1); 22(2); 23(2); 24(1)
58(1); 59(1); 60(1); 61(1); 62(2); 63(2); 64(1)
17(2); 22(3); 23(2); 24(2); 25(3)
58(2); 60(1); 61(1); 62(2); 63(2); 64(2)
17(2); 18(1); 19(1); 20(1); 22(2); 23(2); 24(1)
58(1); 59(1); 60(1); 61(1); 62(2); 63(2); 64(1)
17(2); 22(3); 23(2); 24(2); 25(3)
58(2); 60(1); 61(2); 62(2); 63(2); 64(3)

Table 1: Overview of dams and offspring used in behavioural assays.
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Age
(days)
70-72
70-72
71-73
71-73
72-74
72-74
73-75
73-75
77-79
77-79
78-81
79-81
81-83
81-83
85-87
85-87
86-88
86-88
87-89
87-89
N/A
N/A
N/A
N/A
117-119
117-119
117-119
117-119

2.3.8 Estrous Cycle Stage Identification

Evidence suggests that the estrous cycle may affect behavioural measures such
as anxiety, depression (D’Souza & Sadananda, 2017), cognition (Cordeira et al., 2018),
sociability (Chari et al., 2020), and sensitivity to addictive drugs (Lacy et al., 2016;
Quiñones-Jenab et al., 1999; Sell et al., 2005). To determine whether and how the
estrous cycle may affect our behavioural results, the estrous cycle stage for each female
rat was determined through vaginal smears immediately after each behavioural test. To
do this, a dropper with sterile saline was inserted into the vagina and flushed. A few
drops of the sample were dropped onto a glass slide and viewed under a light
microscope. The estrous cycle stage was identified as either proestrus, estrus metestrus,
or diestrus based on the types of cells present in the sample (Marcondes et al., 2002). A
vaginal smear from the proestrus stage was classified as a sample that contains mostly
nucleated epithelial cells. The estrus stage contained predominantly cornified cells. The
metestrus stage was identified when the sample contained an even distribution of
nucleated epithelial cells, cornified cells, and leukocytes. Finally, the diestrus cycle was
recognized as a sample that contained mostly leukocytes (Marcondes et al., 2002). The
phases of the estrous cycle are classified according to the concentrations of circulatory
progesterone and estrogen levels (Perez et al., 2019). The proestrus and estrus phases
are the periods when the progesterone and estrogen levels are high whereas the
metestrus and diestrus stages are when levels of these hormones are low (Perez et al.,
2019). Thus, behavioural differences between proestrus + estrus and metestrus +
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diestrus may be attributed to the different concentrations of circulating hormones.
When analyzing the effects of estrous cycle phases on behavioural results, several
studies group the proestrus + estrus and the metestrus + diestrus specimens in this way.
(Chari et al., 2020; Cordeira et al., 2018; D’Souza & Sadananda, 2017; Perez et al., 2019).
This thesis used the same grouping method.

2.3.9 Statistical Analysis

For the conditioned place preference test, the two-way repeated measures
ANOVA was used to measure and compare the preferences for the saline- vs morphinepaired environments in the vehicle vs THC offspring. For most other behavioural tests,
the independent samples t-test was used to compare behaviour between vehicle and
THC offspring. To investigate the effects of the estrous cycle on behaviour, the
independent samples t-test was used to compare the proestrus + estrus group with the
metestrus + diestrus group for each of the vehicle and THC female offspring separately.
To analyze the estrous cycle impact on the conditioned place preference results, the
independent samples t-test was conducted on the morphine preference scores
calculated (time in morphine context/(time in morphine context + time in saline
context). When a significant difference was found between the proestrus + estrus or the
metestrus + diestrus group of either the vehicle or THC treated rats, we next
investigated whether THC has different effects on the proestrus + estrus and the
metestrus + diestrus groups. To do this, additional independent samples t-tests were
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done to investigate the effects of THC vs vehicle on the proestrus + estrus and the
metestrus + diestrus groups separately. The Mann-Whitney U test was used instead of
the independent samples t-test when a nonparametric test was required.

2.4 Electrophysiology

Intraperitoneal injections of urethane (1.4g/kg) were used to anesthetize rats for
in-vivo single-unit extracellular recordings. When rats were fully anesthetized, they were
held in place in a stereotaxic frame. A heating pad was placed under the rats to maintain
their body temperatures at 37oC. A scalpel was used to make an incision down the skull
and a hand drill was used to make a small hole above the VTA, mPFC, and/or the vHipp.
The following coordinates were used for the regions: VTA: AP: -5.1 to -5.3 mm from
bregma; LM: ±0.7 to ±1.0 mm; and DV: -7.0 to -9.0 mm below the dural surface. mPFC:
AP: +2.8 to +3.2mm from bregma; ±LM: 0.8 to ±1.0mm; and DV: -2.5 to -3.5mm below
the dural surface. vHipp: AP: -5.6mm to -6.0mm from bregma; LM: ±5.0mm; and DV: 6.5mm to -7.0mm below the dural surface. These coordinates were based on a
stereotaxic rat brain atlas by Paxinos and Watson (The Rat Brain in Stereotaxic
Coordinates 6th Edition). Glass microelectrodes (2mm diameter) were pulled with the
PE-21 microelectrode puller (Narishige) to have an average impedance between 6 to 10
MΩ and were filled with sodium acetate (2M) that contained a solution of 2%
pontamine sky blue. A hydraulic micropositioner (Kopf Instruments) was used to bring
the tip of the electrode to the region of interest. The MultiClamp700B amplifier
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(Molecular Devices) was used to amplify the incoming extracellular signals. To record
these signals, the Digidata1440A acquisition system (Molecular Devices) was used in
combination with the pClamp software version 10.7 (Molecular Devices). The
extracellular recordings were filtered (0.3-5 kHz) and sampled at 25 kHz. The activity of
neurons was recorded for 5 minutes and measured 3 specific parameters: 1. Frequency
of spikes (Hz); 2. Bursts/min; and 3. Percentage of spikes firing within bursts.
Neuronal recordings in the VTA were distinguished as either dopamine or GABA
neurons based on well-established criteria. Specifically, the following criteria were used
to identify dopamine cells: 1. Either a biphasic or triphasic waveform action potential
with a >1.1 ms duration from the start to the trough of the negative portion of the
action potential (Ungless & Grace, 2012); 2. An action potential frequency between ~0.5
to 10 Hz (Marinelli & McCutcheon, 2014); and 3. A firing pattern that consists of
irregular interspike intervals and bursting activity (Ungless & Grace, 2012). A burst was
classified as an event with two or more consecutive spikes within a <80 ms interval as
used previously (Hudson et al., 2019; Norris et al., 2016). GABA neurons were identified
with the previously described criteria (Hudson et al., 2019; Norris et al., 2016): 1. An
action potential duration < 1ms; 2. An action potential frequency greater than 10 Hz;
and 3. A regular firing pattern without bursting activity.
Neuronal recordings in the PFC were identified as glutamate neurons based on
previously established criteria (Parsegian et al., 2011): 1. Waveform shape; 2. An action
potential frequency less than 10 Hz; and 3. A >2.5 ms duration action potential. A burst
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was classified as an event with 3 consecutive spikes within an interval of <45 ms as used
previously (Renard, Szkudlarek, et al., 2017).
Neuronal recordings in the vHipp were identified as glutamate neurons if the
baseline frequency was approximately 0.25 to 6.0 Hz as described previously
(Goonawardena et al., 2011).
The independent samples t-test was used to compare the vehicle vs THC
neuronal baseline activity in the PFC, VTA, and vHipp. The Mann-Whitney U test was
used instead of the independent samples t-test when a nonparametric test was
required.
After the final recording, the position of the electrode tip was stained with an
ejection of the 2% pontamine blue solution by application of a -20μA current in the
electrode for 15 minutes. Brains were then removed and fixed in a 25% sucrose-formalin
solution. Brains were sliced into 60 μm sections in a cryostat and stained with neutral
red. A light microscope was used to confirm the correct placement of recording sites.
Several brains did not have 2% pontamine blue stains for unknown reasons. In these
cases, the light microscope was used to confirm traces of electrode tracts in the regions
of interest. In addition, one of the PFC and vHipp brain samples were severely damaged
during extraction. In these cases, the inclusion criteria were based on the coordinates
used for the recordings and the similarity of these neurons’ waveforms with recordings
within the same region from other rats.
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Recording
VTA dopamine
recordings

Sex

Group

n-size

M

VEH
THC
VEH
THC
VEH
THC
VEH
THC
VEH
THC
VEH
THC
VEH
THC
VEH
THC

5
2
2
5
5
2
2
4
4
4
3
3
3
2
3
3

F
VTA GABA
recordings

M
F

PFC glutamate
recordings

M
F

vHipp glutamate
recordings

M
F

Dam ID that provided
offspring and (# of offspring)
N/A
N/A
N/A
N/A
N/A
N/A
N/A
N/A
17(1); 18(2); 24(1)
59(2); 61(1); 63(1)
17(1); 25(2)
58(1); 62(1); 64(1)
18(2);19(1)
59(1); 61(1)
17(1); 25(2)
58(1); 62(1); 64(1)

Age
(days)
102-164
141-143
152-155
144-150
102-164
141-143
152-155
144-150
71-101
79-86
85-99
88-94
81-103
80-86
85-99
88-94

Table 2: Overview of dams and offspring used in electrophysiology.

2.5 MALDI IMS

2.5.1 Tissue Preparation

When the offspring reached the 3-week old and 6-month old time points, a
subgroup of the offspring was sacrificed with intraperitoneal injections of Eutanyl
(sodium pentobarbital 240mg/kg) and their brains extracted. Brain samples were
immediately frozen in dry ice and stored in -80oC before they were sectioned. The
Cryostar NX50 cryostat (ThermoFisher Scientific) was used to obtain coronal brain
sections (14µm in thickness) that contained the PFC, NAc, and vHipp. The PFC sections
were collected between +2.52mm to +3.24mm from bregma. The NAc sections were
from +2.28mm to +2.76mm from bregma. The vHipp sections were obtained from
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between -4.68mm to -5.64mm from bregma. These coordinates were based on the
stereotaxic rat brain atlas by Paxinos and Watson (The Rat Brain in Stereotaxic
Coordinates 6th Edition). Four sections were placed onto conductive glass slides coated
with indium in oxide. On each slide, 2 sections were from one vehicle rat and the other 2
sections were from a THC rat. Glass slides were then stored in -20oC. Prior to
sublimation, the glass slides were placed in a desiccator for 10 minutes.

2.5.2 Matrix Sublimation

A sand bath on a hot plate was heated to 240oC. On the floor of the outer
sublimation apparatus, 250mg of 1,6-diphenyl-1,3,5-hexatriene (DPH) matrix was evenly
spread. A metal plate was taped to the bottom side of the inner sublimation apparatus
(the condenser). The glass slide with the brain samples was taped onto the metal plate
so that the side with the samples was directly facing the matrix. The inner and outer
parts of the sublimation apparatus were tightly sealed together. Crushed ice was placed
in the condenser and then filled with water until the ice floated. A cold trap apparatus
was placed in a cold trap container filled with ethanol (300ml). Two small pieces of dry
ice was placed into the cold trap container. Rubber tubes were used to connect the
input of the cold trap to the sublimation apparatus while the output of the cold trap was
connected to a vacuum pump. The vacuum pump was turned on to achieve a vacuum
(30 to 50mT) inside the sublimation apparatus. The pump was left on for 5 minutes
before sublimation to ensure that the pressure inside the sublimation apparatus reaches
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an equilibrium state. After 5 minutes, the sand bath was raised using a scissor lift until it
fully supported the sublimation apparatus. After 2 minutes, the sublimation apparatus
was removed from the sand bath. The glass slide was removed from the apparatus and
stored in -20oC overnight before MALDI IMS.

2.5.3 MALDI IMS

The glass slide with samples were placed in a desiccator for 10 minutes. Four
small spots of matrix next to each of the brain slices were wiped off so that the four
spots formed a rectangular configuration around each of the brain slices. To externally
calibrate the mass spectrometer, standards were prepared using the following formula:
5µl of α-cyano-4-hydroxycinnamic acid (CHCA, 5mg/ml); 2µl of lyso-phosphatidic acid
(LPA, 1mg/ml); and 2 µl of ethanol (50%). Standards (0.4µl ) were pipetted onto each of
the spots. After the standards dried, the glass slides were placed in the SCIEX 5800
MALDI tandem time-of-flight mass spectrometer (SCIEX). Standards were used to
externally calibrate the system at between ±50 to ±150ppm mass tolerance. The
reflectron negative ion mode was used to acquire the imaging data within the mass-tocharge ratio (m/z) range of 100 to 500 m/z. The distance between each pixel was 70µm.
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2.5.4 Imaging Data Processing

The MSiReader software was used to obtain a peak intensity curve that
presented the relative abundance (Y-axis) by m/z (X-axis). The area under the peak
intensity curve corresponding to the abundance of DHA (327.3 m/z) was used to
calculate the relative level of DHA in the brain regions of interest. The level of DHA in
the brain region of interest was compared in the THC vs vehicle treated sample from the
same glass slide. Specifically, the DHA level from the THC-treated rat was divided by that
of the vehicle-treated sample that was mounted on the same slide to obtain one data
point. This experiment was repeated with different pairs of animals and the data points
were compared to a test value of 1.0 using a one-sample t-test.
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Region
PFC PrL MALDI
(3-weeks old)

Sex Group n-size
M
F

PFC IL MALDI
(3-weeks old)

M
F

NAc core MALDI
(3-weeks old)

M
F

NAc shell MALDI
(3-weeks old)

M
F

vHipp CA1 MALDI
(3-weeks old)

M
F

vHipp VS MALDI
(3-weeks old)

M
F

VEH
THC
VEH
THC
VEH
THC
VEH
THC
VEH
THC
VEH
THC
VEH
THC
VEH
THC
VEH
THC
VEH
THC
VEH
THC
VEH
THC

4
4
5
5
4
4
6
6
4
4
4
4
4
4
4
4
4
4
6
6
3
3
6
6

Dam ID that provided offspring and
(# of offspring)
11B(1); 17(1); 22(1); 24(1)
50W(1); 58(1); 59(1); 63(1)
11W(2); N/A(3)
50BB(2); N/A(3)
11B(1); 17(1); 22(1); 24(1)
50W(1); 58(1); 59(1); 63(1)
11W(2); 11B(1); N/A(3)
50BB(3); N/A(3)
11B(1); 17(1); 22(1); 24(1)
50W(1); 58(1); 59(1); 63(1)
11(1); N/A(3)
50BB(1); N/A(3)
11B(1); 17(1); 22(1); 24(1)
50W(1); 58(1); 59(1); 63(1)
11W(1); N/A(3)
50BB(1); N/A(3)
11W(1); 11B(1); 22(1); 24(1)
50W(2); 59(1); 63(1)
11W(2); 11B(1); N/A(3)
50BB(3); N/A(3)
11B(1); 22(1); 24(1)
50W(1); 59(1); 63(1)
11W(2); 11B(1); N/A(3)
50BB(3); N/A(3)

Table 3: Overview of dams and offspring used in MALDI IMS (3-weeks old).
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Region
PFC PrL MALDI
(6-months old)

Sex Group

n-size

M

5
5
6
6
4
4
6
6
5
5
6
6
5
5
6
6
5
5
6
6
5
5
6
6

F
PFC IL MALDI
(6-months old)

M
F

NAc core MALDI
(6-months old)

M
F

NAc shell MALDI
(6-months old)

M
F

vHipp CA1 MALDI
(6-months old)

M
F

vHipp VS MALDI
(6-months old)

M
F

VEH
THC
VEH
THC
VEH
THC
VEH
THC
VEH
THC
VEH
THC
VEH
THC
VEH
THC
VEH
THC
VEH
THC
VEH
THC
VEH
THC

Dam ID that provided offspring and
(# of offspring)
16OO(1); 14w(1); 14BB(1); 15RR(1); 15PP(1)
54B(1); 56BB(1); 54W(1); 56O(1); 55PP(1)
16OO(1); 14W(1); 15PP(1); 15RR(1); 14BB(2)
56O(1); 56BB(1); 54B(1); 55P(1); 54W(1); 56G(1)
14W(1); 14BB(1); 15RR(1); 15PP(1)
54B(1); 56BB(1); 54W(1); 56O(1)
16OO(1); 14W(1); 15PP(1); 15RR(1); 14BB(2)
56O(1); 56BB(1); 54B(1); 55P(1); 54W(1); 56G(1)
16OO(1); 14w(1); 14BB(1); 15RR(1); 15PP(1)
54B(1); 56BB(1); 54W(1); 56O(1); 55PP(1)
16OO(1); 14W(1); 15PP(1); 15RR(1); 14BB(2)
56O(1); 56BB(1); 54B(1); 55P(1); 54W(1); 56G(1)
16OO(1); 14w(1); 14BB(1); 15RR(1); 15PP(1)
54B(1); 56BB(1); 54W(1); 56O(1); 55PP(1)
16OO(1); 14W(1); 15PP(1); 15RR(1); 14BB(2)
56O(1); 56BB(1); 54B(1); 55P(1); 54W(1); 56G(1)
16OO(1); 14w(1); 14BB(1); 15RR(1); 15PP(1)
54B(1); 56BB(1); 54W(1); 56O(1); 55PP(1)
16OO(1); 14W(1); 15PP(1); 15RR(1); 14BB(2)
56O(1); 56BB(1); 54B(1); 55P(1); 54W(1); 56G(1)
16OO(1); 14w(1); 14BB(1); 15RR(1); 15PP(1)
54B(1); 56BB(1); 54W(1); 56O(1); 55PP(1)
16OO(1); 14W(1); 15PP(1); 15RR(1); 14BB(2)
56O(1); 56BB(1); 54B(1); 55P(1); 54W(1); 56G(1)

Table 4: Overview of dams and offspring used in MALDI IMS (6-months old).

3 Results

3.1 Behavioural Test Results

Behavioural tests were used to investigate the effects of prenatal THC on
schizophrenia-associated behaviours including locomotion (Van Den Buuse, 2010),
anxiety (Grillo, 2018; C. M. Powell & Miyakawa, 2006), memory (Aleman et al., 1999),
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sociability (Dodell-Feder et al., 2015; C. M. Powell & Miyakawa, 2006), anhedonia
(Horan et al., 2006), and drug dependence (Khokhar et al., 2018).

3.1.1 Open Field

The open field test was used to determine whether prenatal THC treatment
affects locomotor activity and anxiety in male and female offspring. In male offspring,
prenatal THC treatment did not induce significant differences in horizontal distances
travelled (t(18) = -2.069, p = 0.053) and the time spent in the center (t(18) = -1.98, p =
0.063). However, there was a slight trend for increased distance travelled and time
spent in the center by the prenatal THC-treated male offspring. In the female offspring,
there were no significant differences in the distances travelled (t(22) = 1.023, p = 0.318)
or time spent in the center (t(22) = -0.607, p = 0.55) (Figure 2). Investigation into the
effects of the estrous cycle on locomotion revealed that while the estrous cycle does not
have an effect on vehicle rats (t(10) = -0.52, p = 0.615), locomotion is significantly
decreased in the metestrus + diestrus rats compared to proestrus + estrus rats exposed
to THC (t10) = 3.291, p = 0.008). To determine whether THC induces different locomotor
effects on different estrous cycle phases, the effects of THC was investigated within rats
at the proestrus + estrus phases and metestrus + diestrus phases separately. No
significant locomotor effects of THC were found within the proestrus + estrus phase rats
(t(13) = 0.291, p = 0.775) or the metestrus + diestrus phase rats (t(7) = 1.691, p = 0.135). In
the vehicle rats, there was a significant decrease in the time spent in the center by the
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metestrus + diestrus rats vs the proestrus + estrus rats (t(8.942) = 3.454, p = 0.007). This
difference was abolished in the prenatal THC exposed rats (t(10) = -0.011, p = 0.992).
However, THC did not have a significant effect on the proestrus + estrus group (t (13) =
0.291, p = 0.775) or the metestrus + diestrus group (t(4.204) = -1.301, p = 0.26) when
analyzed separately. In the vehicle rats, n = 8 and n = 4 were in the proestrus + estrus
and metestrus + diestrus groups respectively. In the THC rats, n = 7 and n = 5 were in the
proestrus + estrus and metestrus + diestrus groups respectively. Overall, these findings
suggest that prenatal THC does not affect distance travelled and anxiety in both male
and female offspring.
Fig. 2A
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Fig. 2B

Fig. 2C

40

Fig. 2D

Figure 2: Open field test. No significant differences in A) horizontal distance travelled or B) time spent in
center by vehicle vs prenatal THC-treated male offspring. No significant differences in C) distance travelled
or D) time spent in center by vehicle vs prenatal THC-treated female offspring.

3.1.2 Light Dark Box

The light dark box test was used to determine how prenatal THC treatment
affects anxiety levels in male and female offspring. Prenatal THC treatment in male
offspring did not induce any significant effects on the first transition latency (t(11.60) =
0.607, p = 0.555), second transition latency (U = 37, p = 0.79), transition count (U = 31, p
= 0.339), and time spent in the light box (U = 39, p = 0.929). In the female offspring,
prenatal THC did not have any significant effects on first transition latency (t(21) = 0.534,
p = 0.599), transition count (t(21) = -0.778, p = 0.445), and time spent in the light box (t(21)
= -0.115, p = 0.909). However, prenatal THC treatment significantly increased the second
transition latency in female offspring (t(12.45) = -2.847, p = 0.014) (Figure 3). There were
no significant differences in the first transition latency between the proestrus + estrus
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and the metestrus + diestrus groups within the vehicle (t(9) = -0.949, p = 0.368) or THCexposed (t(10) = 0.269, p = 0.793) rats. Similarly, the estrous cycle did not affect the total
transition count within the vehicle (U = 5.5, p = 0.099) or THC-exposed (t(10) = -1.321, p =
0.216) offspring. Within the vehicle rats, the estrous cycle did not affect the second
transition latency either (t(9) = 0.681, p = 0.513). However, within the THC-treated rats,
the second transition latency was significantly lower in the metestrus + diestrus group vs
the proestrus + estrus group (t(7.947) = 3.694, p = 0.006). Further investigation into the
differential effects of THC on the proestrus + estrus and metestrus + diestrus groups
separately revealed that compared to vehicle, prenatal THC significantly increases the
second transition latency of rats in the proestrus + estrus phase (t(7.095) = -3.843, p =
0.006). When comparing the rats in the metestrus + diestrus phase, prenatal THC did
not induce any significant differences in the second transition time. In the vehicle rats,
the time spent in the light box was significantly increased in the metestrus + diestrus vs
the proestrus + estrus phases (t(9) = -2.728, p = 0.023). This difference was abolished in
the THC-treated rats (t(10) = -0.786, p = 0.45). Upon further investigation into the
potential estrous-cycle dependent effects of THC on the time spent in the light box, no
significant differences were found within the proestrus + estrus (t (12) = -0.543, p = 0.597)
or the metestrus + diestrus (t(7) = 0.78, p = 0.461) groups. In the vehicle rats, n = 7 and n
= 4 were in the proestrus + estrus and metestrus + diestrus groups respectively. In the
THC rats, n = 7 and n = 5 were in the proestrus + estrus and metestrus + diestrus groups
respectively. Overall, these findings suggest that prenatal THC induces anxiety in female,
but not male offspring. Moreover, estrous cycle data analysis suggests that the overall
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anxiogenic effect by THC in female offspring may be driven by THC’s effect on the
proestrus + estrus rats.
Fig. 3A

Fig. 3B
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Fig. 3C

Fig. 3D

44

Fig. 3E

Fig. 3F
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Fig. 3G

Fig. 3H

Figure 3: Light dark box test. No significant effects of prenatal THC treatment in male offspring on A) first
transition latency, B) second transition latency, C) transition count, and D) time spent in the light box. In
female offspring, prenatal THC significantly increased the F) second transition latency but did not have any
significant effects on E) first transition latency, G) transition count, and H) time spent in the light box.
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3.1.3 Novel Object Recognition

The novel object recognition test was used to determine the effects of prenatal
THC administration on short-term memory in male and female offspring. Prenatal THC
did not induce any significant differences in the novel object recognition scores in both
male (t(18) = 0.657, p = 0.519) and female offspring (t(22) = 0.633, p = 0.533) (Figure 4).
The stages of the estrous cycle did not affect novel object recognition in the vehicle (t (10)
= 0.848, p = 0.416) and THC (t(10) = 0.923, p = 0.378) female offspring. In the vehicle rats,
n = 9 and n = 3 were in the proestrus + estrus and metestrus + diestrus groups
respectively. In the THC rats, n = 8 and n = 4 were in the proestrus + estrus and
metestrus + diestrus groups respectively. Overall, these findings suggest that in male
and female offspring, short-term memory is not affected by prenatal THC exposure.
Fig. 4A
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Fig. 4B

Figure 4: Novel object recognition test. In both A) male and B) female offspring, prenatal THC did not
induce and significant effects on the object recognition scores.

3.1.4 Spontaneous Alternation Y-Maze

The spontaneous alternation Y-maze was used to measure the effects of prenatal
THC treatment on working memory in male and female offspring. No significant
differences in alternation scores were observed due to prenatal THC administration in
male (t(18) = -0.568, p = 0.577) and female (t(21) = 1.735, p = 0.097) (Figure 5). In the
vehicle female offspring, rats in the proestrus + estrus group demonstrated a
significantly higher alternation score than those in the metestrus + diestrus group (t(9) =
4.256, p = 0.002). This difference was abolished in the THC offspring (t (10) = 1.738, p =
0.113). To determine whether THC has different effects on different estrous cycle
phases, the effects of THC was investigated within rats at the proestrus + estrus phases
and metestrus + diestrus phases separately. Compared to vehicle, THC did not induce
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any significant differences in the proestrus + estrus rats (t (14) = 1.641, p = 0.123) and the
metestrus + diestrus rats (t(5) = 2.136, p = 0.086). In the vehicle rats, n = 7 and n = 4 were
in the proestrus + estrus and metestrus + diestrus groups respectively. In the THC rats, n
= 9 and n = 3 were in the proestrus + estrus and metestrus + diestrus groups
respectively. Overall, these findings show that prenatal THC does not affect working
memory in male and female offspring.
Fig . 5A
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Fig. 5B

Figure 5: Spontaneous alternation Y-maze. In both A) male and B) female offspring, there were no
significant differences in alternation score due to prenatal THC administration.

3.1.5 Social Interaction

The social motivation and social recognition tests were used to measure the
effects of prenatal THC administration on sociability and social recognition memory
respectively in male and female offspring. There was not a significant difference in male
social motivation scores due to treatment with prenatal THC (t(17) = 0.389, p = 0.702).
However, prenatal THC induced a significant decrease in social recognition scores in
male offspring (t(18) = 2.147, p = 0.047). In female offspring, prenatal THC did not have
any significant effects on the social motivation scores (t(22) = 0.758, p = 0.457) and social
recognition scores (t(22) = 0.18, p = 0.859) (Figure 6). Social motivation scores were not
affected by the estrous cycle in the vehicle (t(10) = -0.067, p = 0.948) and THC (t(10) =
0.927, p = 0.376) female offspring. Similarly, the estrous cycle did not have a significant
effect on social recognition memory in the vehicle (t(10) = 0.411, p = 0.69) and THC (t(10) =
50

0.421, 0.683) female offspring. In the vehicle rats, n = 7 and n = 5 were in the proestrus
+ estrus and metestrus + diestrus groups respectively. In the THC rats, n = 7 and n = 5
were in the proestrus + estrus and metestrus + diestrus groups respectively. Altogether,
these findings suggest that in male offspring, prenatal THC exposure induces social
memory deficits but does not affect social motivation. In female offspring, neither social
motivation nor social recognition is affected by prenatal THC exposure.
Fig. 6A
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Fig. 6B

Fig. 6C
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Fig. 6D

Figure 6: Social interaction test. Prenatal THC treatment in male offspring did not affect A) social
motivation scores but significantly decreased B) social recognition scores. In female offspring, prenatal
THC did not significantly affect C) social motivation and D) social recognition scores.

3.1.6 Sucrose Preference

The sucrose preference test was used to measure the effects of prenatal THC on
anhedonia in male and female offspring. Exposure to prenatal THC did not have an
effect on sucrose preference scores in male offspring (t(17) = 0.869, p = 0.397). In female
offspring, however, prenatal THC exposure lead to a significant decrease in the sucrose
preference score (t(13.28) = 2.591, p = 0.022) (Figure 7). The estrous cycle did not
significantly affect sucrose preference in the vehicle (t(10) = 1.779, p = 0.106) and THC
(t(10) = -1.255, p = 0.238) female rats. In the vehicle rats, n = 10 and n = 2 were in the
proestrus + estrus and metestrus + diestrus groups respectively. In the THC rats, n = 9
and n = 3 were in the proestrus + estrus and metestrus + diestrus groups respectively.
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Overall, these results show that prenatal THC induces anhedonia in female, but not male
offspring.
Fig. 7A

Fig. 7B

Figure 7: Sucrose preference test. In A) male offspring, prenatal THC exposure did not affect sucrose
preference scores. In B) female offspring, however, prenatal THC exposure significantly decreased sucrose
preference scores.
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3.1.7 Sub-Threshold Morphine Conditioned Place Preference

The sub-threshold morphine condition place preference test was used to
determine whether prenatal THC exposure increases the susceptibility of male and
female offspring to what is normally a sub-threshold dose of morphine. Two-way
repeated measures ANOVA did not reveal a significant group (vehicle vs prenatal THC)
by treatment (saline vs morphine) interaction effect in male (F(1,37) = 0.159; p = 0.695)
and female (F(1,47) = 0.17; p = 0.684) offspring (Figure 8). The estrous cycle did not
significantly affect morphine context preference in the vehicle (U = 13, p = 0.926) and
THC (U = 14, p = 0.57) female rats. In the vehicle rats, n = 9 and n = 3 were in the
proestrus + estrus and metestrus + diestrus groups respectively. In the THC rats, n = 7
and n = 5 were in the proestrus + estrus and metestrus + diestrus groups respectively.
Overall, these results suggest that prenatal THC does not affect sensitivity to morphine
in male and female offspring.
Fig. 8A
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Fig. 8B

Figure 8: Sub-threshold morphine conditioned place preference test. In both the A) male and B) female
offspring, there was not a significant group by treatment interaction effect.

3.2 Electrophysiology Results

To explore potential mechanisms implicated in the above behavioural deficits,
we next searched for impairments in neurological activity states in key brain regions
implicated in schizophrenia. Specifically, we measured the effects of prenatal THC
exposure on the baseline activity states of dopamine and GABA neurons in the VTA as
well glutamate neurons in the PFC and vHipp.

3.2.1 VTA Dopamine Recordings

Prenatal THC exposure to male offspring significantly increased baseline
dopamine activity. Specifically, prenatal THC exposure induced a significant increase in
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the baseline frequency of firing (t(30.88) = -2.752, p = 0.01) as well as the rate of bursting
activity events per minute (U = 74.5, p = 0.014) in male offspring. In female offspring,
however, prenatal THC administration did not induce significant differences in baseline
dopamine frequency (t(25) = 0.129, p = 0.898) and bursts per minute (U = 65.5, p = 0.326)
(Figure 9). Overall, these findings suggest prenatal THC amplifies VTA dopamine
signaling in the male but not female offspring. This raises the possibility that enhanced
VTA dopamine signaling in male offspring may be involved in the behavioural deficits
observed in male offspring exposed to prenatal THC.
Fig. 9A
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Fig. 9B

Fig. 9C
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Fig. 9D

Figure 9: VTA dopamine single-cell extracellular recordings. Prenatal THC exposure to male offspring
significantly increased baseline VTA dopamine neuron A) frequency and B) bursts/min. No significant
differences were observed in the baseline VTA dopamine C) frequency and D) bursts/min in female
offspring.

3.2.2 VTA GABA Recordings

The two-tailed Mann-Whitney U test and independent samples t-test revealed
that prenatal THC exposure did not affect baseline VTA GABA frequency in male (U =
107.5, p = 0.304) and female (t(31) = 0.67, p = 0.508) offspring respectively (Figure 10).
Overall, these findings show that prenatal THC has no significant effect on VTA GABA
interneuron signaling.
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Fig. 10A

Fig. 10B

Figure 10: VTA GABA single-cell extracellular recordings. Prenatal THC treatment did not cause any
significant differences in baseline VTA GABA frequency in A) male and B) female offspring.

3.2.3 PFC Glutamate Recordings

The two-tailed Mann-Whitney U test revealed that in male offspring, prenatal
THC administration did not significantly affect baseline PFC glutamate frequency (U =
60

780.5, p = 0.866) and bursting events per minute (U = 727, p = 0.493). In female
offspring, however, the Mann-Whitney U test demonstrated that prenatal THC
significantly increased baseline PFC glutamate frequency (U = 201, p = 0.003) and the
rate of burst events per minute (U = 233.5, p = 0.015) (Figure 11). Overall, these results
suggest that prenatal THC does not affect male offspring PFC glutamate states but
amplifies PFC glutamate signaling in female offspring which may contribute to the
behavioural deficits observed in the female rats.
Fig. 11A
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Fig. 11B

Fig. 11C
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Fig. 11D

Figure 11: PFC glutamate single-cell extracellular recordings. Prenatal THC did not induce significant
differences in baseline PFC glutamate A) frequency and B) bursts/min in male offspring. In female
offspring, prenatal THC significantly increased baseline PFC glutamate C) frequency and D) bursts/min.

3.2.4 vHipp Glutamate Recordings

The two-tailed Mann-Whitney U test revealed a significant decrease in the
baseline vHipp glutamate frequency in the prenatal THC-exposed male offspring (U =
171.5, p = 0.026). In contrast, The Mann-Whitney U test revealed a significant increase
in baseline vHipp glutamate frequency in female offspring due to prenatal THC exposure
(U = 209.5, p = 0.008) (Figure 12). Overall, these findings suggests that the observed
male and female behavioural deficits may be linked to vHipp glutamate hypoactivity and
hyperactivity respectively.
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Fig. 12A

Fig. 12B

Figure 12: vHipp glutamate single-cell extracellular recordings. In A) male and B) female offspring,
prenatal THC significantly decreased and increased baseline vHipp glutamate frequency respectively.

3.3 MALDI IMS Results

Given the above findings that prenatal THC induced schizophrenia-related
behavioural and neuronal deficits, we next investigated at the molecular level, potential
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effects of prenatal THC that may be linked to the observed behavioural and neuronal
impairments. Specifically, we investigated the impact of prenatal THC exposure on the
levels of brain DHA which may be linked to schizophrenia (McNamara, Jandacek, et al.,
2007). DHA abundance was measured in the PFC (PrL and IL regions), NAc (core and
shell regions), and the vHipp (CA1 and VS regions) at 3-weeks and 6-months old time
points.

3.3.1 MALDI IMS 3-Week Old Males

In 3-week old males, the two-tailed one sample t-test revealed that prenatal THC
did not significantly impact DHA abundance in the PrL (t (3) = -2.28, p = 0.107), IL (t(3) = 0.781, p = 0.492), NASh (t(3) = -0.966, p = 0.405), CA1 (t(3) = -1.653, p = 0.197), and VS (t(2)
= -2.13, p = 0.167). However, DHA abundance was significantly reduced in the NAcc of
prenatal THC-exposed 3-week old males (t(3) = -4.349, p = 0.022) (Figure 13). Overall,
these findings raise the possibility that DHA deficiency in specifically the NAcc may be
involved in the behavioural and neuronal impairments observed in male offspring.
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Fig. 13E

DHA Quantification in CA1 (3-week old male)
1.2

Ratio (THC/VEH)

1
0.8
0.6
0.4
0.2
0
Test Value

CA1 (n=4)

Fig. 13F

68

Fig. 13G

Figure 13: MALDI IMS on 3-week old males. In 3-week old males, prenatal THC did not have a significant
effect on A) PrL, B) IL, C) NASh, E) CA1, and F) VS DHA abundance. The D) NAcc of prenatal THC-exposed 3week old males exhibited a significant reduction in DHA levels. G) Sample experiment showing the
difference in NAcc (outlined in pink) relative DHA abundance between vehicle (left) and THC (right)
offspring.

3.3.2 MALDI IMS 6-Month Old Males

In 6-month old male offspring, the two-tailed one sample t-test revealed that
prenatal THC does not affect DHA abundance in the PrL (t(4) = -1.257, p = 0.277), NAcc
(t(4) = 0.318, p = 0.766), NASh (t(4) = -0.769, p = 0.485), and VS (t(4) = -1.117, p = 0.326). In
contrast, prenatal THC significantly decreased DHA levels in the IL (t(3) = -8.215, p =
0.004) and CA1 (t(4) = -2.952, p = 0.042) (Figure 14). Overall, these findings indicate that
prenatal THC induces long-term DHA deficits in the IL and CA1.
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Fig. 14C
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Fig. 14E

Fig. 14F
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Fig. 14G

Figure 14: MALDI IMS on 6-month old males. In 6-month old males, DHA levels were not significantly
different in the A) PrL, C) NAcc, D) NASh, and F) VS. Prenatal THC significantly reduced DHA levels in the B)
IL and E) CA1 of 6-month old male offspring. G) Sample experiment showing the difference in CA1
(outlined in pink) relative DHA abundance between vehicle (left) and THC (right) offspring.

3.3.3 MALDI IMS 3-Week Old Females

The two-tailed one sample t-test revealed that prenatal THC did not affect DHA
levels in the NASh (t(2) = -2.259, p = 0.109) and caused a slight non-significant reduction
in the VS (t(5) = -2.502, p = 0.054) of 3-week old females. In contrast, prenatal THC
significantly reduced DHA abundance in the PrL (t(4) = -7.143, p = 0.002), IL (t(5) = -3.001,
p = 0.03), NAcc (t(3) = -3.397, p = 0.043), and CA1 (t(5) = -2.872, p = 0.035) of 3-week old
female offspring (Figure 15). Overall, these findings suggest that prenatal THC
significantly reduces DHA levels in the PrL, IL, NAcc, and CA1.
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Fig. 15E
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Fig. 15G

Figure 15: MALDI IMS on 3-week old females. In 3-week old females, there were no significant differences
in the DHA levels of D) NASh and F) VS. Prenatal THC significantly decreased DHA levels in the A) PrL, B) IL,
C) NAcc, and E) CA1. G) Sample experiment showing the difference in PrL (outlined in pink) relative DHA
abundance between vehicle (left) and THC (right) offspring.

3.3.4 MALDI IMS 6-Month Old Females

In 6-month old females, the two-tailed one sample t-test revealed that prenatal
THC did not significantly affect the DHA abundance in the PrL (t (5) = 0.377, p = 0.722), IL
(t(5) = 0.49, p = 0.645), NAcc (t(5) = 0.533, p = 0.617), NASh (t(5) = 0.527, p = 0.621), CA1
(t(5) = -0.347, p = 0.743), and VS (t(5) = -0.5, p = 0.638) (Figure 16). Overall, these findings
raise the possibility that female offspring can effectively recover from DHA deficiency
caused by prenatal THC exposure.
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Fig. 16C
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Fig. 16E
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Figure 16: MALDI IMS on 6-month old females. In 6-month old females, there were no significant
differences in DHA levels of the A) PrL, B) IL, C) NAcc, D) NASh, E) CA1, and F) VS.

4 Discussion

This project stems from previous studies from our laboratory which show that
chronic THC exposure during adolescence, a critical neurodevelopmental period
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(Renard, Rosen, et al., 2017), leads to the development of schizophrenia-associated
symptoms in male rats (Renard, Rosen, et al., 2017; Renard, Szkudlarek, et al., 2017). To
add to these findings, the present study reveals that in both male and female offspring,
chronic THC exposure during prenatal development alters behaviour, neuronal activity
states, and brain omega-3 composition to resemble changes observed in schizophrenia.
Interestingly, these findings also suggest that prenatal THC exposure may have different
effects on male and female offspring.
Behavioural results from this study reveal that in the case of male offspring, THC
exposure during prenatal neurodevelopment leads to significant deficits in social
recognition memory consistent with previous findings from our laboratory (Renard,
Rosen, et al., 2017; Renard, Szkudlarek, et al., 2017). Interestingly, however, the effects
of prenatal THC administration were not fully consistent with those of adolescent THC
treatment. For example, while adolescent THC treatment has been reported to decrease
sociability, we did not detect any differences in social motivation scores in the male
offspring. This suggests that social motivation is only affected by THC when
administered after prenatal development. Our results from the open field test also show
that in male offspring, prenatal THC may induce a slight, but non-significant increasing
trend in locomotor activity. This is in contrast to our previous findings that suggest
adolescent THC treatment decreases locomotion (Renard, Rosen, et al., 2017; Renard,
Szkudlarek, et al., 2017). However, hyperlocomotion is considered to reflect some of the
positive symptoms of schizophrenia and increased motor activity may be attributed to
amplified dopaminergic activity (Van Den Buuse, 2010). This aberrant state of dopamine
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signaling is believed to underlie schizophrenia pathophysiology (Brisch et al., 2014). Our
results from the open field test also suggest that in male offspring, prenatal THC leads to
a slight, but non-significant anxiolytic effect that is reflected by the increasing trend in
the time spent in the center zone. This is the opposite of what was expected given our
previous studies which found that chronic adolescent THC exposure induces a significant
anxiogenic effect (Renard, Rosen, et al., 2017; Renard, Szkudlarek, et al., 2017). One
potential explanation may be that the slight increase in exploratory behaviour by the
prenatal THC administration lead to a simultaneous increase in time spent in the center
zone. In support of this possibility, our findings from the light dark box test reveal that in
male offspring, prenatal THC administration does not produce a significant anxiolytic
effect. Notably, in the male offspring, there were no significant differences in the first
transition latency, second transition latency, total transition count, and the time spent
in the light box. Given that adolescent THC has been shown to significantly increase and
decrease second transition latencies and transition numbers respectively (reflective of
increased anxiety), this suggests that THC may only induce anxiety in later stages of
early development after the prenatal period. However, this analysis is limited to a single
assay (Light-Dark Box) and it is possible that anxiogenic effects may have been observed
in other behavioural tests, such as the elevated plus maze. Future studies are required
to more fully examine these potential effects. In the male offspring, there were no
significant differences in the novel object recognition, spontaneous alternation Y-maze,
sucrose preference, and subthreshold morphine conditioned place preference tests
which suggest that prenatal THC does not affect short-term memory, working memory,
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anhedonia, and sensitivity to opiates respectively, at least in the tests used in the
present series of studies. Thus, it remains possible that more subtle cognitive deficits
may be present but were simply not detectable in the present series of pre-clinical tests.
Unlike in the male offspring, prenatal THC exposure to female offspring had an
anxiogenic effect as shown by the significant increase in the second transition latency.
This finding is consistent with our previous findings with adolescent THC exposure albeit
in male rats (Renard, Rosen, et al., 2017; Renard, Szkudlarek, et al., 2017). The sucrose
preference test also shows that prenatal THC exposure to females induces anhedonia
and this fits with previous findings that adolescent treatment with THC or THC analogs
induces anhedonia in male and female rats (Bambico et al., 2010; Realini et al., 2011;
Renard et al., 2016; Rubino et al., 2008). Furthermore, while prenatal THC in male
offspring significantly decreases social recognition memory and causes a non-significant
increasing trend in locomotion, there are no such differences found in female offspring.
Similar to what was seen in the male offspring however, prenatal THC administration to
female offspring did not affect social motivation, novel object recognition, spontaneous
alternation Y-maze, and subthreshold morphine conditioned place preference.
Interestingly, our results of the morphine conditioned preference is inconsistent with
that of an older study which found that prenatal THC exposure significantly increases
the vulnerability of female offspring to morphine dependence (Vela et al., 1998).
However, these results may be attributed to the greater dose of morphine (1mg/kg) as
well as the higher dose (5mg/kg) and longer exposure (gestational day 5 until weaning)
to THC. Together, these findings suggest that prenatal THC exposure may increase the
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susceptibility of female offspring to the addictive properties of morphine at higher doses
but not subthreshold doses. Investigation into the potential behavioural differences
between proestrus + estrus vs metestrus + diestrus female rats revealed that the estrus
cycle does not significantly affect results from the novel object recognition, social
interaction, sucrose preference, and sub-threshold morphine conditioned place
preference tests. However, there were significant differences between the proestrus +
estrus vs metestrus + diestrus in the open field, light dark box, and the spontaneous
alternation Y-maze. In the open field test, the metestrus + diestrus vehicle rats displayed
significantly lower time spent in the center vs the proestrus + estrus vehicle rats. This is
consistent with previous findings that rats in the proestrus + estrus phase display
decreased anxiety (D’Souza & Sadananda, 2017). Interestingly, this difference between
estrous cycle phases was abolished in the THC-treated rats. Further investigation to
determine potential estrous cycle-dependent effects of THC revealed no significant
differences between vehicle and prenatal THC when the proestrus + estrus and the
metestrus + diestrus groups were analyzed separately. While no estrous cycle-induced
locomotor differences were found in the vehicle rats, the metestrus + diestrus rats
showed decreased locomotion in the THC-treated rats which suggest that THC may have
estrous cycle dependent locomotor effects. However, separate analysis of the proestrus
+ estrus and the metestrus + diestrus rats revealed that THC does not induce significant
locomotor effects in these rats. Inconsistent with the findings that the proestrus + estrus
stages are linked to decreased anxiety (D’Souza & Sadananda, 2017), our metestrus +
diestrus rats showed increased time spent in the light box vs the proestrus + estrus
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vehicle rats. This difference was abolished in the THC-treated rats, but further analysis
revealed that THC does not affect time spent in the light box when proestrus + estrus
and metestrus + diestrus rats are analyzed separately. Although estrous cycle-induced
second transition latency differences were not observed in the vehicle rats, the
metestrus + diestrus group displayed a significantly lower second transition latency in
the prenatal THC offspring. Interestingly, separate analysis of the proestrus + estrus and
the metestrus + diestrus groups revealed that THC only increases second transition
latency in the proestrus + estrus rats. This suggests that the observed overall increase in
female second transition latency by THC is specific to the proestrus + estrus stages and
may not be generalized to all estrous cycle phases. Lastly, in the vehicle rats, the
metestrus + diestrus group achieved significantly lower alternation scores. This is
inconsistent with past findings that the estrus cycle does not affect working memory
(Pompili et al., 2010; Stackman et al., 1997). In the THC-treated rats, this difference in
working memory was not abolished. Further investigation revealed THC does not impact
alternation scores when the proestrus + estrus and the metestrus + diestrus groups are
analyzed separately. Altogether, these findings suggest that the estrus cycle did not
impact the behavioural effects of THC except in the light dark box where THC
significantly increases the second transition time in rats at the proestrus + estrus stages
but not the metestrus + diestrus stages. It is interesting to note that a recent study
reported that this same procedure for THC administration did not affect the levels of
circulatory estrogen (Gillies et al., 2020) which raises the possibility that the estrouscycle dependent effects of THC in the light dark box may be due to the different levels of
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progesterone. Future studies are required to examine the potential relationship
between THC and progesterone levels.
Overall, these behavioural findings suggest that prenatal THC exposure induces
social memory deficits and potentially hyperlocomotion in male offspring whereas the
same treatment to female offspring results in amplified anxiety and anhedonia. This is
consistent with past evidence that male schizophrenia patients experience more severe
memory deficits (Han et al., 2012) whereas schizophrenia in females is associated with
more affective symptoms (Cotton et al., 2009).
We previously found that adolescent THC administration leads to augmented
baseline VTA dopaminergic activity which may be implicated in the manifestation of
schizophrenia-related symptoms (Renard, Rosen, et al., 2017). To add to this discovery,
the present study reports key findings that prenatal THC exposure also leads to
hyperdopaminergic states in the VTA as well as impairments in the neuronal activity of
the PFC and vHipp which are two regions involved in VTA dopamine regulation
(Almodóvar-FÁBREGAS et al., 2002; Lodge & Grace, 2011). Specifically, in male offspring,
prenatal THC exposure lead to a significant increase in baseline VTA dopamine
frequency and bursts/min as seen with adolescent THC treatment (Renard, Rosen, et al.,
2017). Unexpectedly, however, prenatal THC-exposed male offspring did not display PFC
glutamate hyperactivity and had a significant decrease in vHipp glutamate activity. As
mentioned previously, PFC glutamate neurons project glutamate neurons to the VTA to
provide excitatory tone (Almodóvar-FÁBREGAS et al., 2002) whereas the vHipp (anterior
hippocampus in humans) projects excitatory glutamate neurons to the NAc which
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provides inhibitory tone onto the VTA (Lodge & Grace, 2011). Therefore, it is expected
that amplified glutamate signaling in the PFC and vHipp leads to increased VTA
dopamine release. Given that the present study did not find any significant differences
in the PFC glutamate activity of prenatal THC-exposed males, this suggests that aberrant
PFC glutamate signaling is not implicated in the observed behavioural impairments or
VTA hyperdopaminergic signaling. Likewise, the fact that prenatal THC did not increase
glutamatergic signaling in the vHipp of male offspring suggests that the aberrant vHipp
is not involved in the observed hyperdopaminergic signaling in the VTA. Although
anterior hippocampus hyperactivity is normally associated with schizophrenia
symptomology (Grace, 2016), brain hypoactivity is implicated with the later stages of
schizophrenia (Bast et al., 2017) which suggests that hippocampus hypoactivity may play
a role in the observed behavioural impairments by the prenatal THC-exposed males.
In contrast to the effects on male offspring, prenatal THC exposure to female
offspring did not affect VTA dopamine activity but significantly amplified glutamatergic
signaling in the PFC and vHipp. Our previous research has also shown that chronic THC
treatment in male adolescent rats induces PFC glutamate hyperactivity (Renard,
Szkudlarek, et al., 2017). However, the same study also found that adolescent THC
significantly increases baseline VTA dopamine activity (Renard, Szkudlarek, et al., 2017).
Given that the PFC projects excitatory tone onto the VTA, it is plausible that the
observed VTA dopamine hyperactivity may be attributed to the increase in excitatory
glutamatergic signaling from the PFC. In the present study, it is unclear why the
augmentation of glutamatergic signaling in the PFC and vHipp did not translate to an
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increase in VTA dopaminergic activity specifically in the female cohorts. However, one
potential explanation may be derived from evidence that while the positive symptoms
of schizophrenia are linked to mesolimbic dopamine hyperactivity, the negative
symptoms may be attributed to dopaminergic hypoactivity of the mesocortical pathway
(Brisch et al., 2014) which are VTA dopamine projections to the cortical brain regions
such as the PFC (Willing & Wagner, 2016). While male offspring did not show any
negative symptoms due to prenatal THC treatment, prenatal THC-exposed female
offspring demonstrated significantly higher levels of anhedonia, a negative symptom of
schizophrenia (Patel et al., 2014). Thus, it is possible that prenatal THC leads to
hypoactivity of the VTA cortical dopamine projections in female but not male offspring.
In vivo single-unit recordings of these suppressed cortical projections may have
cancelled out the hyperactivity of mesolimbic dopamine projections. Future research is
necessary to determine whether and how prenatal THC affects the activity of
mesolimbic and mesocortical dopamine projections separately.
It is interesting to note that prenatal THC induced the opposite effects on the
baseline vHipp glutamate activity in male and female offspring. While prenatal THCexposed male offspring displayed dampened vHipp activity which may be associated
with the later stages of schizophrenia, the females demonstrated vHipp hyperactivity
which has been implicated with schizophrenia-related symptoms (Grace, 2016; Wolff et
al., 2018). Given that all electrophysiology recordings were conducted on the same
batch of animals, these results suggest that female offspring progress through the
phases of schizophrenia slower than male offspring. Consistent with this hypothesis,
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evidence suggests that compared to females, males have an earlier onset of
schizophrenia (Segarra et al., 2012). Future research is needed to determine whether
vHipp hypoactivity in prenatal THC-exposed males is an effect that is consistent at
earlier ages or if it is an effect only observed during their late stages of schizophrenia.
Studies that investigate the effects of prenatal THC exposure in male and female
offspring are very limited. One recent study by Frau et al. investigated the
schizophrenia-related effects of chronic prenatal THC exposure on pre-adolescent male
and female offspring. Notably, the study found that prenatal THC treatment alone does
not induce hyperactivity, anxiety, or prepulse inhibition (PPI) deficits (Frau et al., 2019),
a trait of schizophrenia where a prior sensory stimulus fails to properly dampen the
startle reflex by a subsequent stimulus (Takahashi et al., 2011). Moreover, in-vivo
microdialysis of the NASh did not reveal any effects of prenatal THC exposure alone on
dopamine concentrations which suggests that prenatal THC does not affect mesolimbic
dopamine activity. Interestingly, however, Frau et al. found that a challenge dose of THC
induces hyperactivity, PPI deficits, and enhanced NASh dopamine levels of male prenatal
THC-exposed offspring. With whole-cell patch-clamp recordings, the study also found
that there was an increase in basal VTA dopamine frequency of prenatal THC-exposed
male offspring. In contrast, the challenge dose of THC did not affect PPI in prenatal THCexposed female offspring and therefore, all other experiments were done on male
offspring only (Frau et al., 2019). These effects of male prenatal THC exposure on VTA
dopamine activity and locomotion are similar to those observed in our current study.
However, the results by Frau et al. supports a “two-hit” model of psychiatric disorders
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which states that a “first-hit” caused by genetic or environmental factors may increase
the risk of neurological deficits due to a “second-hit” in the future (Frau et al., 2019).
The prenatal THC administration, which acted as the “first-hit” in Frau’s study, did not
have an effect until those rats were also exposed to the challenge dose of THC which
was the “second-hit” (Frau et al., 2019). This raises the possibility that in our behavioural
tests that did not reveal a significant effect, a challenge dose of THC to the prenatal THCexposed rats may induce a significant effect. Future studies are needed to determine
how a challenge dose of THC would affect the results of the open-field, light dark box,
novel object recognition, spontaneous alternation-Y maze, social interaction, and subthreshold morphine conditioned place preference tests.
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Figure 17: Summary of behavioural and electrophysiology results. Summary of the effects of THC on
behaviour and neuronal activity states in the PFC, VTA, and ventral hippocampus. Abbreviations: DA =
dopamine; GLUT = glutamate.

Given the current results, it is difficult to propose a unitary mechanism that may
underlie the wide array of behavioural and neurobiological abnormalities induced by

90

prenatal THC exposure. However, our MALDI-IMS results raise the possibility that the
effects of prenatal THC in the current study may be linked to DHA deficiency. In 3-week
old male offspring, prenatal THC significantly decreased DHA abundance in the NAcc
whereas the 6-month old male offspring had significantly reduced DHA levels in the IL
and CA1 regions. In 3-week old female offspring, DHA concentrations were significantly
reduced in the PrL, IL, NAcc, and CA1 due to prenatal THC exposure while no differences
were observed in the 6-month old female offspring. As mentioned previously, evidence
suggests that brain omega-3 deficiency is linked to depression, anxiety (Carrié et al.,
2000; DeMar et al., 2006; Harauma & Moriguchi, 2011; Larrieu & Layé, 2018;
McNamara, Hahn, et al., 2007), and mesolimbic dopamine hyperactivity (Zimmer et al.,
2002). Moreover, clinical studies have shown that schizophrenia patients have lower
omega-3 concentrations in the brain (McNamara, Jandacek, et al., 2007) as well as the
blood (Hoen et al., 2013; van der Kemp et al., 2012) which translates to lower omega-3
delivery to the brain (Weiser et al., 2016). Together, these findings implicate omega-3
deficiency in the effects of prenatal THC and schizophrenia pathophysiology. Conversely,
omega-3 supplementation has been shown to improve anxiety (Buydens-Branchey et
al., 2008; Song et al., 2003), depression (Carlezon et al., 2005; Haberka et al., 2013;
Lakhwani et al., 2007), and cognition (Bauer et al., 2014; Külzow et al., 2016). In patients
diagnosed with schizophrenia, research also suggests that omega-3 supplementation
may improve symptoms (Pawełczyk et al., 2016; Peet et al., 1996). Interestingly, omega3 administration has even been shown to prevent psychosis in individuals at risk of
developing psychotic disorders (Amminger et al., 2015). Omega-3 is an essential human
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nutrient (Kitajka et al., 2004) and diet is the brain’s primary source for omega-3 (Dyall,
2015). Thus, it is plausible that omega-3 supplementation may increase brain omega-3
levels and that the beneficial effects of omega-3 is directly linked to enhanced brain
omega-3 levels. It is unclear how omega-3 abundance may regulate schizophreniarelated symptoms and neuronal activity states. However, one interesting possibility is
that omega-3 produces its regulatory effects through the activation of peroxisome
proliferator activated receptor gamma (PPARg). PPARg is a nuclear transcription factor
that binds omega-3 (Edwards & O’Flaherty, 2008) and is expressed in various brain
regions that include the PFC, NAc (Warden et al., 2016), VTA (Sarruf et al., 2009), and
the hippocampus (Inestrosa et al., 2005). Emerging evidence suggests that PPARg
activation may have beneficial effects on measures such as anxiety, depression
(Beheshti et al., 2019; Kurhe & Mahesh, 2016), cognition (Wang et al., 2012) and
addiction (De Guglielmo et al., 2015; Jones et al., 2017; J. M. Schmitz et al., 2017;
Stopponi et al., 2011). Furthermore, evidence suggests that PPARg agonism may
contribute to the regulation of VTA dopamine activity (De Guglielmo et al., 2015). Cells
that express PPARg are organized alongside GABA cells and evidence suggests that
PPARg signaling inhibits VTA dopamine release through the stimulation of inhibitory
GABA signaling (De Guglielmo et al., 2015). Specifically, de Guglielmo et al. has shown
with ex-vivo electrophysiology that pre-incubation of brain samples in the PPARg agonist
pioglitazone blocks the amplification of VTA dopamine activity by the application of
morphine. The study also found that while morphine application decreases the
inhibitory postsynaptic currents (IPSCs) from the rostromedial tegmental nucleus
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(RMTg), the posterior area of the VTA, pre-incubation with pioglitazone restores the
IPSCs (De Guglielmo et al., 2015). The RMTg is a region that projects inhibitory GABA
neurons to the VTA and thus regulates VTA dopaminergic signaling (De Guglielmo et al.,
2015). Given these findings that PPARg activation can increase GABA signaling, this
raises the possibility that PPARg regulates VTA dopamine activity through the
modulation of GABA signaling. If true, this theory would be consistent with our findings
which suggest that DHA deficiency in the PFC, NAc, and vHipp may be linked to
dopamine hyperactivity and therefore the schizophrenia-related effects of prenatal THC
administration. Low DHA concentrations in the NAc, PFC, and vHipp would translate to
reduced PPARg activation and thus an attenuation of inhibitory GABA interneuron
signaling in these regions. In the NAc, dampened GABA interneuron signaling would
increase its inhibitory influence onto the VP which would decrease the VP’s inhibitory
tone onto the VTA. In the PFC and vHipp, lower GABA interneuron signaling would
ultimately result in glutamate hyperactivity and contribute to VTA dopamine
hyperactivity. This theory also fits with the established hypothesis that GABA
dysfunction is implicated in schizophrenia pathophysiology (Marques et al., 2020).
In the present study, prenatal THC significantly decreased NAc (core region) DHA
levels in the 3-week old males while in the 6-month old males, DHA was reduced in the
PFC (infralimbic region) and vHipp (CA1 region). As expected, these results
corresponded with VTA dopamine hyperactivity in prenatal THC-exposed male offspring.
Interestingly, however, we did not find any differences in PFC glutamate activity despite
the fact that prenatal THC reduced DHA levels in the IL region of 6-month old males.
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One possible reason for these conflicting results could be that the rats’ age at which the
electrophysiology recordings were conducted were in-between the two time-points at
which the DHA quantification studies were done. For example, given that PFC DHA
concentrations were decreased in the 6-month but not the 3-week old male offspring, it
is possible that the corresponding increase in PFC glutamate activity would only be
observed closer to 6-months of age. Additionally, the reduction of vHipp glutamate
activity of the prenatal THC-exposed male offspring was the opposite of what would be
expected from the decrease in DHA of the CA1 region in 6-month old males exposed to
prenatal THC. This raises the possibility that the reduction in CA1 DHA could be a
compensatory mechanism to counter the significant reduction of vHipp glutamate
signaling.
In the 3-week old female offspring, DHA levels were reduced in the PFC (PrL and
IL), NAc (core region), and the vHipp (CA1 region). These results match our proposed
theory that low PPARg activation due to insufficient DHA leads to PFC and vHipp
hyperactivity because we found that prenatal THC significantly increases glutamate
activity in the PFC and vHipp. Unexpectedly, there were no differences in VTA dopamine
activity given these changes in DHA concentrations. As previously mentioned, however,
it is possible that prenatal THC lead to hypoactivity of the mesocortical dopamine
projections from the VTA and cancelled out the amplification effects on mesolimbic
dopamine neurons. It is also interesting to note that the effects of prenatal THC on DHA
levels were apparent in 3-week old, but not 6-month old females. These findings suggest
that unlike male offspring, female offspring may be able to fully recover from the effects
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of prenatal THC on brain DHA concentrations. Further research is needed to determine
the mechanisms underlying the ability of the female brain to naturally recover from DHA
deficits due to prenatal THC exposure.

4.1 Implications

The current study adds to the growing body of evidence that THC exposure
during neurodevelopmental periods can induce schizophrenia-related symptoms.
However, this is the first study to investigate in both males and females the effects of
prenatal THC on neurological activity states and DHA levels which may underlie the
behavioural effects of THC. A greater understanding of such mechanisms that may
contribute to the gender differences in schizophrenia could prompt research towards
more personalized, sex-dependent treatments that may, for example, target different
brain regions of male vs female patients. In addition, the current findings that
insufficient brain DHA may contribute to the effects of prenatal THC and schizophreniarelated symptoms suggest that omega-3 supplementation may mitigate some of the
psychotropic effects of cannabis and improve symptoms in schizophrenia patients.
Omega-3 is a common dietary supplement and evidence suggests that there are no
significant health risks linked to its use (Reimers & Ljung, 2019). Thus, omega-3 could be
a flexible co-treatment option compatible with other drugs.
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4.2 Limitations

Without investigating the effects of a THC challenge dose on prenatal THCexposed offspring, we have an incomplete understanding of prenatal THC’s behavioural
consequences. Although the “first-hit” alone can induce neurological deficits, evidence
suggests that prenatal THC as a “first-hit” may not induce some schizophrenia-related
effects alone and may require the “second-hit”, a THC challenge dose, to observe the
schizophrenia-related measures (Frau et al., 2019). Therefore, further studies with THC
challenge doses are needed to better understand the behavioural consequences of
prenatal THC on locomotion, anxiety, cognition, anhedonia, and sensitivity to addictive
drugs.
Another limitation is that, as mentioned previously, our VTA electrophysiology
recordings may have included both mesolimbic and mesocortical VTA dopamine
projections because with these recordings alone, we cannot decipher between
mesolimbic and mesocortical VTA dopamine projections. This is an issue as
schizophrenia is implicated with mesolimbic dopamine hyperactivity and mesocortical
dopamine hypoactivity (Brisch et al., 2014). Although there were no differences in the
female VTA dopamine activity, there may still have been differences in mesolimbic
and/or mesocortical dopamine signaling. To gain a better understanding of prenatal
THC’s effects on mesolimbic and mesocrotical dopamine activities, different techniques
such as microdialysis can be used to measure the levels of dopamine in the terminal
regions of the mesolimbic and mesocortical dopamine systems.
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Lastly, while the MALDI IMS data provides valuable insight on the potential
mechanisms implicated in THC’s effects as well as schizophrenia pathophysiology, there
are two limitations to these results. Firstly, the current sample sizes for each of the
groups are low and therefore, dissonant data points currently have a significant impact
on the results. Secondly, as seen from the current study, the results on brain DHA
concentrations may change from the 3-week old time point to the 6-month old time
point. Given that the behavioural and electrophysiology experiments were conducted in
between these two time periods, it is more difficult to implicate the MALDI IMS findings
with our behavioural and electrophysiology results.

4.3 Future Steps

The decrease in brain DHA levels due to prenatal THC exposure suggest that DHA
deficiency may be implicated in the schizophrenia-related effects seen in this study.
However, it is still unknown whether omega-3 supplementation can block these effects.
Therefore, future experiments will investigate the effects of prenatal omega-3
supplementation when combined with prenatal THC administration.
In our previous adolescent THC studies, we have also shown that adolescent THC
induces aberrant expression levels of proteins that may be related to schizophrenia
pathophysiology (Renard, Rosen, et al., 2017; Renard, Szkudlarek, et al., 2017). For
example, one study has shown that adolescent THC exposure significantly decreases
levels of GAD67, a protein marker for GABA neuron localization, in the PFC which is
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similar to what is seen in schizophrenia patients (Renard, Szkudlarek, et al., 2017).
Therefore, this raises the possible explanation that the PFC hyperactivity observed in the
study may be due to reduced levels of GABAergic interneurons in the PFC (Renard,
Szkudlarek, et al., 2017). Investigation into prenatal THC’s effects on the expression
levels of such proteins may further elucidate the molecular mechanisms underlying the
effects of THC as well as schizophrenia pathophysiology.

5 Conclusions

This study adds to the growing body of evidence that prenatal THC exposure can
have deleterious neuropathological consequences on offspring. However, this study is
the first to reveal in male and female offspring the effects of prenatal THC on
mesocorticolimbic neurological activity states and DHA abundance as potential factors
underlying the schizophrenia-associated effects of prenatal THC. The elucidation of
mechanisms underlying the effects of prenatal THC and gender differences in
schizophrenia may lead to the development of more personalized, sex-oriented
treatment options that may be more effective in blocking the psychotropic effects of
THC or improving schizophrenia-related symptoms.
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